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CHAPTER 1: Introduction
1.1 Breast Cancer: A Review
While billions of dollars have been designated to cancer research, care, and
education, the number of people developing this disease is still on the rise. Early
detection and better treatments have increased survival for almost all types, but cancer
is still the second leading cause of death in the United States, after heart disease. More
effective treatment options need to be developed to increase survival rates for patients.
The focus of this dissertation is a combination targeted therapy for triple negative breast
cancer (TNBC) and the molecular mechanisms of the therapy.
Breast cancer is the second leading cause of cancer related deaths and remains
the most diagnosed among American women. It is estimated that in 2013 there were
232,340 new cases and 39,620 deaths attributed to breast cancer in women,
accounting for 14% of all female cancer incidence. The lifetime risk for a woman to
develop breast cancer is one in eight, with the highest risk of development occurring at
70 years or older (ACS, 2013).
Public awareness of the disease has been greatly increased by organizations
such as Susan G Komen for the Cure, and campaigns such as “October is Breast
Cancer Awareness Month” and the Pink Ribbon. Many women are routinely getting
mammograms and checking for early detection, but even early detection has not greatly
reduced breast cancer related mortality. Public awareness and knowledge about breast
cancer has increased to the level where women are actively advocating for more
effective treatments and better survival rates. The influx of research dollars from
fundraising organizations and campaigns has led to many advances in the field but

	
  

	
  

2	
  
	
  
much is still unknown about the etiology of breast cancer and the most effective
treatments.
Breast cancer is a very heterogeneous disease and can be characterized into
four molecular subtypes based on gene expression profiling: Luminal A, Luminal B,
HER2+, and Basal (Goldhirsch et al., 2011; Schnitt, 2010). Table 1 describes these
subtypes and the current therapeutic options. The guidelines are meant to serve as a
reference for physicians to treat the individual patient based on a variety of other clinical
and pathological factors. These include patient age, overall health, and the stage and
grade of the tumor (Schnitt, 2010). Age is often a factor in relation to menopause status.
Hormone therapy is often reserved for post-menopausal women or as a last option for
pre-menopausal women as the side effects from hormone ablation are greater in the
pre-menopausal population (ACS, 2013). The subtypes have different incidence and
mortality rates. Luminal A cancers comprise 40% of all diagnosed breast cancers and
according to data from the Carolina Breast Study, have an 84% survival rate. Luminal B
cancers are less prevalent at 20% but have a slightly better prognosis with an 87%
survival rate. HER2+ cancers have a good molecular target and drug, trastuzumab, but
their survival rate is only 52%, and the subtype comprises 10-15% of all breast cancers.
The basal-like subtype is predominantly TNBC but not all basal cancers are TNBC and
not all TNBC is basal-like. Basal-like cancers had a prognosis of 75% in the Carolina
cohort. It also comprises about 20% of breast cancers (Carey et al., 2006). Basal-like
tumors, particularly TNBC, are highly aggressive and have a poor prognosis compared
to the most common luminal cancers so we need to find a better treatment option that
has low toxicity and combats developed resistance for TNBC patients.
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1.1.1 Stage and Grading
Stage and grade information was gathered from the National Comprehensive
Cancer Network Clinical Practice Guidelines in Oncology, Breast Cancer, version
2.2012 (NCCN, 2012). Stage and grade are used to classify solid tumors. Both are
important indicators for prognosis and are useful in determining how a patient is to be
treated. For instance, if a patient has a low grade and stage tumor, that patient is most
likely treated with radiation and/or surgical resection, often breast conserving, is
proposed. Hormone therapy might also be recommended for the patient. Later stage
and grade tumors are often indicators of poor prognosis and must be treated with
aggressive chemotherapy when the patient is able to tolerate the high doses. Stage 4
disease indicate the tumor has metastasized to distant lymph nodes and parts of the
body, therefore palliative care is the only treatment option in hopes of extending life.
Common sites of metastasis for breast cancer include the lungs, liver, bones and brain.
Staging is based on TNM where T is the size of the tumor, N is lymph node
involvement, and M is the presence or absence of metastasis. T can be subdivided into
T0 or the absence of a primary tumor; T1 where the tumor is ≤20mm; T2 where the
tumor is >20mm but ≤50mm; a T3 tumor is >50mm; and T4 in breast cancer indicates
the tumor has invaded the chest wall and/or skin. Regional lymph node involvement is
measured as the N staging where N0 is no node involvement; N1 is detectable
metastasis to a movable ipsilateral level I,II axillary lymph node; N2 in clinically fixed or
matted ipsilateral level I,II or internal mammary nodes without axillary node detection;
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Figure 1: Breast lymph nodes.

Staging is based on TMN system. Lymph node
involvement within the breast is an important indicator of
stage and can dictate treatment options. Cancer cells
detected in the supraclavicular, intraclavicular, and
internal mammary lymph nodes is more advanced
disease and staged N3. Image reproduced with
permission from American Cancer Society.
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N3 metastasis in ipsilateral infraclavicular (level III axillary), internal mammary nodes, or
ipsilateral supraclavicular lymph nodes (Figure 1). M is used to indicate the presence or
absence of metastasis. M0 means there is no detectable distant metastasis in the body
where M1 is the detection of metastasis, the extent of metastasis is unnecessary for
TMN staging (NCCN, 2012).
Grade is based on the histological characterization of the tumor. G1 indicates a
low grade where the cancer cells are more differentiated and generally have a more
favorable prognosis; G2 cells have an intermediate histology where cells are less
differentiated but the prognosis is still moderately favorable; G3 is the least favorable
grade and indicates that the tumor cells are poorly differentiated (NCCN, 2012).
1.1.2 Triple Negative Breast Cancer
TNBC is a highly malignant and aggressive subtype of breast cancer. While it
encompasses 12-20% of all diagnosed breast cancers, it is responsible for a disparate
number of breast cancer related deaths (Chacon and Costanzo, 2010; Schneider et al.,
2008). Premenopausal African American women are likely to develop TNBC at a
disproportionate rate compared to white counterparts for reasons that are currently
unknown (Stead et al., 2009). TNBC is characterized by a lack of receptor
overexpression (ER [estrogen receptor], PR [progesterone receptor], and HER2) and
therefore the commonly used hormone targeted and HER2 driven antibody therapies
are ineffective against the subtype. Part of the high mortality rate associated with TNBC
is due to the aggressive nature of basal-like cancers. A large proportion of TNBC
tumors are basal-like and often have higher histological grade, a high Ki67 index,
marked cellular pleomorphism, increased mitotic activity, and atypical mitotic figures
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Table 1: Molecular subtypes, characteristics, and treatment.

Molecular
Subtype
Luminal A

Biomarker
Profile
ER+ and/or PR+,
HER2-, low Ki67
(<14%)

Clinical Features

Treatment

~40% of invasive
breast cancer
Luminal A.

Luminal B
(HER2+ and
HER2-)

Her2-: ER+ and/or
PR+,HER2-,and
high Ki67 (>14%)
Her2+: ER+
and/or
PR+,HER2+, any
Ki67
ER-, PR-, and
HER2+

~20% of invasive
breast cancer
Luminal B.
Higher histological
grade than LumA.

Hormone therapy.
Radiotherapy.
Chemotherapy
variable.
Prognosis better for
LumA than LumB
Hormone therapy.
Radiotherapy.
Chemotherapy better
response in LumB.

ER-, PR-, HER2-,
and CK5/6 and/or
EGFR+

~80% overlap
between ‘TNBC’
and intrinsic
‘basal-like’
subtype.
BRCA1
dysfunction
Often in African
Americans.
Very aggressive
and highly
malignant.

HER2+

Basal

HER2
overexpressed or
amplified.

Trastuzumab
(Herceptin).
Lapatinib
Radiotherapy.
Anthracyclinebased chemotherapy.
Poor prognosis
Adriamycin,
cyclophosphamide,
taxane.
Radiotherapy.
Platinum-based
chemotherapy.
PARP inhibitors.
Poor prognosis.

The four main molecular subtypes of breast cancer are Luminal A (LumA), Luminal
B (LumB), HER2+, and Basal. They are characterized by the presence of the
Estrogen Receptor (ER), the Progesterone Receptor (PR), HER2 Receptor (human
epidermal growth factor 2), Ki67 (MK167), EGFR, and CK5/6 (cytokeratin 5,6)
levels (Cheang et al., 2009; Goldhirsch et al., 2011; Nielsen et al., 2004; Schnitt,
2010).
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(Nielsen et al., 2004; Rakha et al., 2007). These are all characteristics of higher
proliferative potential and poorly differentiated tumor cells. Genomic instability and
increased DNA copy number also contribute to TNBC malignancy (Chin et al., 2006).
TNBC can contain detrimental mutations in p53, increased expression of immune
response genes, and/or BRCA1 mutations (Schneider et al., 2008). BRCA1 alterations
are often associated with TNBC. Mutations in BRCA1 lead to decreased DNA repair
mechanisms and therefore increased genomic mutations and genetic instability. BRCA1
and BRCA2 mutations are responsible for 25% of hereditary breast cancers (Easton,
1999). 90% of all BRCA1 associated tumors are triple negative (Chacon and Costanzo,
2010). With such heterogeneous characteristics, TNBC is difficult to treat and the
genomic instability and variety of mutations along with the growth signaling pathway
alterations make a disease that often develops resistance to many cytotoxic
chemotherapy agents.
TNBC can be subdivided into further histological categories (see Table 2), the
most common type being basal-like. Most TNBC tumors express basal markers such as
the EGFR (epidermal growth factor receptor) and cytokeratins. Lehman and colleagues
divided TNBC into 7 subcategories based on differential gene expression. The
categories can be seen in Table 2 and are as follows: basal-like 1 (BL1); basal-like 2
(BL2); immunomodulatory (IM); mesenchymal

(M); mesenchymal stem–like (MSL);

luminal androgen receptor (LAR); and unstable (UNS) (Lehmann et al., 2011). The IM
subtype has gene expression enriched in the immune cell processes.
characterized by immune signaling in addition to immune cell-surface antigens,
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Table 2: TNBC Subtypes.
	
  
	
  
	
  
Subtype
Basal-like 1 (BL1)
Basal-like 2 (BL2)

Immunomodulatory
(IM)
Mesenchymal-like
(M)
Mesenchymal Stemlike (MSL)
Luminal AR (LAR)

Unstable (UNS)

Associated Pathways
Cell Cycle
DNA replication reactome
RNA Polymerase
EGF Pathway
NGF Pathway
MET Pathway
WNT β-catenin Pathway
CTLA4
IL12 Pathway
Th1/Th2 Pathway
IL7 Pathway
IGF/mTOR Pathway
ECM Pathway
Regulation of Actin by RHO
WNT Pathway
ECM Receptor Interaction
TCR Pathway
WNT β-catenin
Focal Adhesion
Pentose/Glucuronate
Interconversion
Glutathione Metabolism
Tyrosine Metabolism
Steroid Biosynthesis
Cytokeratin Expression
Multiple chromosome
rearrangements

There are 7 TNBC subtypes that are characterized by
differential gene expressions; basal-like 1, basal-like 2,
immunomodulatory, mesenchymal, mesenchymal stem–
like, luminal androgen receptor, and unstable.
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cytokine signaling, complement cascade, chemokine receptors and ligands, and
antigen presentation (Lehmann et al., 2011). The M and MSL subtypes are enriched for
cell motility, ECM receptor interaction, and cell differentiation pathways (Lehmann et
al., 2011). MSL is also enriched for angiogenesis and claudins. The LAR subtype is
characterized

by

increased

steroid synthesis,

porphyrin metabolism,

and

androgen/estrogen metabolism (Lehmann et al., 2011). The different TNBC subtypes
have significant variability in relapse-free survival. LAR has a significant decrease in
relapse-free survival compared to BL1 and IM (Lehmann et al., 2011). The M subtype
also had a lower relapse-free survival compared to BL1, and that for MSL was greater
than M. The MSL subtype had the greatest relapse-free survival while patients with the
LAR subtype had the worst prognosis for relapse-free survival based on Kaplan-Meier
analysis following the patients for 10 years. Lehmann and colleagues found that there
was no significant difference in tumor size or grade at diagnosis between the TNBC
subtypes but women diagnosed with LAR were older compared to the other subtypes
(Lehmann et al., 2011).
These following data concerning surgical resection are from cancer.net and
Kaviani et al., 2013. Most TNBC tumors are surgically resected with administration of
adjuvant chemotherapy and radiation (Gangi et al., 2014). Surgery for the treatment of
breast cancer has changed drastically in the last 30 years. While complete removal of
the breast and all surrounding tissue was once commonplace and left debilitating scars
and largely deformed chests, surgery is now able to effectively remove the tumor
without excising a considerable amount of normal surrounding tissue. The former
surgery was called a radical mastectomy and the entire breast, muscle, and all
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surrounding tissue was completely removed, even up through the armpit and into the
back on certain occasions. The surgery left many women disfigured and reconstruction
of a new breast was not possible. Surgeons were later able to remove less of the
normal breast tissue while still getting clean margins around the edges of the tumor, a
necessity to ensure total removal of cancerous cells in the area. A lumpectomy is now a
common practice for smaller tumors within the breast allowing for removal of the tumor
mass while conserving as much normal tissue as possible. This allows for easier
reconstructive surgery with the remaining tissue and enabling many women to keep the
appearance of a normal breast. In one study, breast-conserving therapy with whole
breast radiation had the same survival rate as a mastectomy for TNBC(Gangi et al.,
2014).
Surgery is most often paired with either radiation and/or chemotherapy in a
neoadjuvant or adjuvant setting. Neoadjuvant chemotherapy is given to reduce the size
of the tumor before surgery. If the oncologist is able to reduce tumor burden, less tissue
can be removed leading to less downtime for the patient and an easier recovery.
Radiation and adjuvant chemotherapy are often given after surgery to ensure removal
of microscopic cancer cells that might have been left behind after the surgery (Kaviani
et al., 2013). TNBC has a greater chance of recurrence after resection than the other
molecular subtypes of breast cancer, therefore; aggressive chemotherapy and radiation
are almost always suggested for these patients (Meyers et al., 2011; Zaky et al., 2011).
Scientists and clinicians are actively working to find a better treatment for women
with TNBC that helps combat the high rate of treatment resistance and tumor
recurrence. The current chemotherapy standard of care for TNBC patients is the
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combination ACT (adriamycin [doxorubicin], cyclophosphamide, and a taxane). Many
ongoing clinical trials are aimed at exploiting the signaling pathways upregulated in
TNBC or DNA repair mechanisms, as BRCA1 and PARP1 (Poly[ADP]ribose
polymerase 1) are often mutated. A current treatment with a relatively good success
rate is an aggressive combination of systemic cytotoxic chemotherapy. 5-fluorouracil (5FU), doxorubicin and cyclophosphamide was shown to have a 45% pathological
complete response (pCR) in a 2005 study (Rouzier et al., 2005). Other studies have
looked at platinums as some TNBCs express BRCA1 mutations, which confer sensitivity
to cisplatin (Byrski et al., 2010; Silver et al., 2010). PARP1 inhibitors have also shown
some success in TNBC and many clinical trials are ongoing to assess their efficacy in
the clinic in Phase I and II trials (NCT01116648, NCT00516724) (Santana-Davila R,
2010; Tutt et al., 2010). Many chemotherapeutic options exist for TNBC but
unfortunately they have not delivered high response rates.
TNBC also expresses receptors that can be inhibited through targeted drugs.
Unlike systemic cytotoxic chemotherapy, targeted agents are more effective at
selectively killing the cancer while sparing a greater number of normal cells. Side effects
of targeted therapies still exist but are often better tolerated than their cytotoxic
counterparts. Many targeted therapies work on the premise of oncogene addiction.
Oncogene addiction is the theory that cancer cells rely on the overexpression of certain
growth factors and receptors, such as EGFR and HER2, therefore when the receptor is
inhibited the cancer cells are less able to adapt to the inhibition and subsequently die.
When this signaling is reduced, normal cells can better adjust and therefore survive;
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opposed to the addicted cancer cells which are more likely to die when the strong
growth stimulus is removed (Malina et al., 2011; Weinstein, 2002).
Further trials are ongoing in TNBC using a combination of EGFR inhibitors and
other cytotoxic chemotherapies such as docetaxel and carboplatin (NCT00491816).
EGFR inhibitors are approved for treatment of non-small-cell lung carcinoma (NSCLC)
(Rosenberg et al., 2004). Antibodies such as cetuximab, and tyrosine kinase inhibitors
(TKIs) such as gefitinib and erlotinib, are used to inhibit the EGFR and its downstream
effectors. As previously mentioned, EGFR is overexpressed (greater than 3-fold) in
TNBC, up to 50%, and therefore could be a potential drug target (Nielsen et al., 2004;
Rakha et al., 2007). Other targets for TNBC therapies are mTOR (mammalian target of
rapamycin) and VEGF (vascular endothelial growth factor). The mTOR inhibitor,
everolimus, is being used in clinical trials in metastatic TNBC disease (NCT00827567)
and in combination with paclitaxel and cisplatin (NCT00930930). VEGF targeted antiangiogenic therapy has also been evaluated with bevacizumab with or without paclitaxel
and/or carboplatin followed by doxorubicin and cyclophosphamide, or bevacizumab as a
single agent (NCT00861705, NCT00528567). Among pathways that are upregulated in
TNBC, mTOR is often activated. Studies have shown that EGFR and mTOR inhibitors
are effective in preclinical models as a combination but their mechanism of action is still
unknown (Bianco et al., 2008; Liu et al., 2011). The combination of EGFR and mTOR
inhibitors in TNBC was explored in the clinic, however, all trials were terminated due to
slow accrual or funding termination before any clinical results were reported. Such trials
included the combination of lapatinib and everolimus (NCT01272141), which was
terminated in March 2014. The mTOR inhibitor, rapamycin was shown to sensitize

	
  

	
  

13	
  
	
  
NSCLC cells that have gained resistance to gefitinib and a similar study showed
everolimus, a rapamycin analog (rapalog), had the same effect (La Monica et al., 2009;
Liu et al., 2011). Colon, pancreatic, and breast cancer cell lines that were resistant to
EGFR TKIs were also sensitized when treated with an mTOR inhibitor but the
mechanism of action is unknown (Bianco et al., 2008; Buck et al., 2006). More about
EGFR and mTOR will be discussed below in upcoming sections.
1.2 Epidermal Growth Factor Receptor
The epidermal growth factor (EGF) was first discovered in 1962 by Stanley
Cohen as an agent that promoted eye opening in newborn mice (Cohen and Carpenter,
1975). Years later Graham Carpenter discovered the receptor (Carpenter et al., 1978).
The EGFR is part of the ErbB/HER family of transmembrane growth factor receptors,
which include four members: EGFR, also known as ErbB1/HER1, ErbB2⁄HER2⁄NEU,
ErbB3⁄HER3, and ErbB4⁄HER4 (Mitsudomi and Yatabe, 2010) (Figure 2). The
deregulation of ErbB (erythroblast leukemia viral oncogene) proteins have been
implicated in the tumorigenesis of many epithelial cancers including lung, breast,
ovarian, pancreatic, and prostate (Hynes and Stern, 1994).
ErbB proteins have four functional domains including a cysteine-rich extracellular
ligand-binding domain, a transmembrane domain, an intracellular tyrosine kinase
domain, and a C-terminal regulatory domain (Burgess et al., 2003; Hynes and Lane,
2005; Riese and Stern, 1998). The ErbB family of receptor tyrosine kinases are
activated in response to a ligand, homo- or heterodimerize, and activate downstream
signaling pathways through tyrosine phosphorylation of different residues on the
intracellular domain (Riese and Stern, 1998). The heterodimerization enables the
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orphan receptor ErbB2/HER2 and the kinase-dead ErbB3/HER3, to initiate signaling
through binding the other family members (Hynes and Lane, 2005). Downstream
pathways activated by the ErbB family include the mitogen-activated protein kinases
(MAPK) cascade (Figure 3 EGFR Y1148) and phosphatidylinositide 3-kinases (PI3K)
activated AKT pathway cascade (Figure 3, EGFR Y1101). Y1148 and Y1101
correspond with the site on the EGFR that when phosphorylated allows for binding and
activation of the respective proteins. P70S6K (70kDA Ribosomal protein S6 kinase) can
also be activated directly by ErbB3 and ErbB4 dimers and indirectly through ErbB1 and
ErbB2 (Yarden and Sliwkowski, 2001).
The four members of the ErbB family can be activated through eight ligands
grouped into three different classes (Figure 2). The first class can only bind EGFR and
contains EGF and its analogs, transforming growth factor alpha (TGF-α) and
amphiregulin (AR), also known as keratinocyte autocrine factor or colorectum-cell
derived growth factor. The second class can bind ErbB3 and ErbB4 and contains the
neuregulins (NRGs) and the neuregulin-2s (NRG-2s), also known as the cerebellumderived growth factors. The final group can bind both EGFR and ErbB4 and contain
heparin-binding epidermal growth factor-like factor (HB-EGF), epiregulin (EPR);
betacellulin (BTC); also known as heregulins (Riese and Stern, 1998). The ErbB family
can also be activated through receptors and signals that do not directly interact with
EGFR. These include hormones, neurotransmitters, lymphokines, and stress inducer
signals demonstrating the diversity of the receptor and its activators (Carpenter, 1999).
The EGFR signaling cascade has been extensively studied as it plays a major
role is many aspects of normal cellular processes including apoptosis, migration,
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growth, adhesion, and differentiation (Figure 2) (Yarden and Sliwkowski, 2001; Yecies
and Manning, 2011). Both the ligand and dimerization partner determines the output
signal from ErbB family members. This interaction allows for the autophosphorylation of
ErbB, recruiting the specific docking proteins to sites of phosphorylation to begin the
signaling cascade (Olayioye et al., 1998). There are three pathways that can be
activated by all ErbB dimerization couples. These include the Ras activated MAPK
cascade, PI3K/ AKT pathway, and P70S6K/p85S6K (Soltoff and Cantley, 1996; Yarden
and Sliwkowski, 2001). While all dimers can activate these pathways, they require
certain docking proteins that can only interact with specific dimers. For example, c-Cbl
is unable to interact with ErbB3, and the receptor is also unable to bind PLCγ, and Grb2
affecting ErbB3’s ability to ubiquitinate and activate the transcription factor Fos (Fedi et
al., 1994). ErbBs can also be trans-activated by GPCRs and heterologous signals
including hormones, neurotransmitters, lymphokines, and stress inducers. Non-receptor
tyrosine kinases such as JAK are also able to directly phosphorylate the kinase part of
the receptor resulting in activation of EGFR dependent pathways (Carpenter, 1999;
Yarden and Sliwkowski, 2001). Most of what is known about ErbB signaling results in
growth and proliferation. Our data suggest that the EGFR pathway also may play a role
in translation through a lesser known and explored mechanism involving eukaryotic
initiation factor 4B (eIF4B). The EGFR function in translation closely links the pathway
with mTOR’s involvement in the same process and provides a potential pathway
crosstalk that is important in TNBC and that this dissertation explores.
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Knockout mice of EGFR have proven its vital role in skin, lungs, and the
gastrointestinal tract with knockout of the receptor being embryonic lethal (Miettinen et
al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995). Of the many pathways that
EGFR is involved in; much research has been done with the EGFR as a typical receptor
tyrosine kinase (RTK) and the start of the RAS/RAF/MEK/ERK cascade (Yarden and
Sliwkowski, 2001). Studying the activation of proteins within the cascade has helped to
understand a substantial amount about RTK signaling through phosphorylation.
HER2 is amplified in 15-30% of invasive ductal carcinomas (Slamon et al., 1987).
Tumors with higher levels of HER2 are generally larger at diagnosis, have greater
lymph node involvement, higher grade, and contain a greater number of proliferative
cells (Yarden and Sliwkowski, 2001). The recognition of HER2 as a druggable target led
to the generation of an antibody to HER2 in 1998, known as herceptin (trastuzumab).
The antibody has been effective at reducing tumor burden in patients with HER2
overexpression through binding and subsequent inhibition of downstream pathways and
internalization. It also induces expression of the cyclin dependent inhibitors, p27Kip1 and
p130, which inhibit the cell cycle, and recruit immune cells (Clynes et al., 2000;
Sliwkowski et al., 1999).
1.2.1 EGFR as a Target in Cancer
Kawamoto and Sato first explored targeting EGFR in cancer in 1983 when they
studied growth inhibition of tumor cells treated with an EGFR antibody (Kawamoto et al.,
1983; Sato et al., 1983). Their experiments had promising results and others since have
also studied inhibition of the EGFR and its downstream signaling pathways in most solid
tumor types (Herbst et al., 2004; Mitsudomi and Yatabe, 2010). The EGFR is involved in
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Figure 2: ErbB family members, ligands, and signaling network.

	
  
	
  
	
  
The ErbB family contains four members; EGFR, Her2, Her3, and Her4. Upon ligand
stimulation the receptors homo- or heterodimerize, cross phosphorylate and activate
downstream signaling pathways through tyrosine kinase activity. Her2 has no ligand
but can dimerize with the other family members while Her3 has no kinase activity and
therefore must heterodimerize with another family member to signal after ligand binding.
This figure is reproduced with permission from Yarden and Sliwkowski, 2001.
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Figure 3: EGFR phosphorylation sites.

	
  
Many sites on the EGFR that, when phosphorylated, induce receptor signaling to a
variety of known proteins. The signaling is further propagated through kinases leading
to pathway activation including cell growth and proliferation. Figure is reproduced with
permission from Wheeler et al., 2010.
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a complex array of signaling networks. It signals for cell proliferation, apoptosis,
adhesion, differentiation, migration, survival, angiogenesis, and tumorigenesis (Wheeler
et al., 2010; Yarden and Sliwkowski, 2001). Its overexpression has been found as a
driving factor in head and neck, breast, bladder, prostate, kidney cancers, NSCLC, and
gliomas (Yarden and Sliwkowski, 2001). It also might be a prognostic indicator in
bladder, prostate cancers, and NSCLC (Gorgoulis et al., 1992; Irish and Bernstein,
1993). In breast cancer it has been found to be a predictor of recurrence after surgical
resection and associated with a shorter disease free and overall survival. The antiproliferative ability of EGFR inhibitors was very promising and led the FDA to approve
five different EGFR inhibitors within three years (gefitinib 2003 for NSCLC, cetuximab
2004 for colorectal cancer, erlotinib 2004 for NSCLC and pancreatic cancer,
panitumumab 2006 for colorectal cancer, laptinib 2006 for breast cancer) (Wheeler et
al., 2010). EGFR inhibitors are effective in these cancers as a common mutation in the
EGFR confers sensitivity to the drugs (L858R). This same mutation is not seen in breast
cancer and therefore leads to resistance to EGFR inhibitors. Since then, EGFR
inhibitors have been used to treat a variety of cancers including lung, colorectal,
pancreatic, and head and neck (Chong and Janne, 2013). One of the most notable
advances is the use of gefitinib and erolitinib to treat metastatic lung cancer patients.
The patients treated with gefitinib or erolitinib had a 74% and 83% response rate
respectively, compared to the other best treatment with progression free survival and
overall survival rates in the 30% (Inoue et al., 2013; Maemondo et al., 2010; Zhou et al.,
2011). The effectiveness of inhibiting the receptor has made EGFR inhibitors part of
standard treatment for NSCLC with increased expression of EGFR.
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Figure 4: Binding sites of EGFR inhibitors.

The EGFR is a transmembrane receptor that, upon ligand binding,
dimerizes and cross phosphorylates to signal. The extracellular side
of the receptor binds the ligand and anti-EGFR antibodies such as
cetuximab and panitumumab. TKIs inhibit the intracellular kinase
activty of the receptor. These small molecules include gefitinib (used
in this dissertation work), erlotinib, AZD9291, and CLO-1686. This
figure was reproduced with permission from Arteaga and Engelman,
2014.
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Two different classes of EGFR inhibitors are used in the clinic, TKIs and
antibodies. TKIs target the kinase activity of EGFR through ATP competitive binding
and include erlotinib, lapatinib, and gefitinib. Monoclonal antibodies, which bind the
receptor to inhibit its activity and promote receptor internalization include cetuximab and
panitumumab (Chong and Janne, 2013) (Figure 4). Gefitinib is prescribed in the clinic
as a 250mg orally available drug that is used daily at a lower concentration than the
maximum tolerated dose resulting in less toxicity (Rukazenkov et al., 2009). Like many
other targeted therapies, gefitinib and erolitinib have a more favorable side-effect profile
then cytotoxics, which often have nausea, diarrhea, and neuropathy as limiting
toxicities. Common reported adverse events with gefitinib are rash and diarrhea
(Maemondo et al., 2010).
There are a multitude of other EGFR inhibitors available for clinical use and
many still waiting for FDA approval. While single agent treatment with EGFR inhibitors
in cancers have not proven to be very effective due to their high levels of resistance,
discussed below, the combination of EGFR inhibitors along with cytotoxic chemotherapy
has proven promising in colorectal and metastatic pancreatic cancers, and especially in
lung cancer (Chong and Janne, 2013; Gschwind et al., 2004).
1.2.2 Mechanisms of Resistance
EGFR inhibitors have been used in the clinic for a variety of cancer types. While
EGFR is a druggable target, its intricate signaling pathways and wide variety of ligands
often allow the cell to remain activated while the EGFR is inhibited. This resistance can
either be acquired or de novo. Acquired resistance occurs when the cell is able to
activate other proteins to compensate for EGFR inactivation. De novo resistance is
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present at onset enabling the cell to completely be independent of EGFR signaling
inhibition with minimal new activation of compensatory mechanisms as seen in acquired
resistance. There are many different ways that cells can circumvent EGFR inhibitors for
either de novo or acquired resistance that are discussed below.
Receptor mutations play an important role in determining sensitivity to EGFR
inhibitors. In the clinic, patients with certain EGFR mutations are more sensitive to
inhibitors while other mutations render resistance. One resistance mutation was
identified in glioblastoma multiforme (GBM) patients who developed insensitivity to
gefitinib. The mutation was a constitutively active truncated version of the receptor
known as EGFRvIII (Wheeler et al., 2010). Another common mutation that patients
develop after prolonged treatment of EGFR TKIs is a substitution in exon 20, T790M.
This residue is considered a “gatekeeper” for the ATP-binding pocket of EGFR.
Resistance may occur when the TKI is no longer able to bind the pocket on the EGFR
due to the larger methionine group and subsequent steric interference (Kobayashi et al.,
2005; Pao et al., 2005).
Angiogenesis is activated by EGFR signaling and is a process that is necessary
for tumor growth and metastasis. During tumor vascularization, blood vessels grow into
the tumor, bringing it nutrients and providing a mechanism for individual tumor cells to
circulate through the body and metastasize. VEGF is a ligand that is necessary to
support angiogenesis and tumors resistant to EGFR inhibitors are known to upregulate
VEGF and its receptor, VEGFR (Viloria-Petit et al., 2001). Activation of the PI3K/AKT
pathway was also found in NSCLC patients who were resistant to gefitinib. Researchers
found that EGFR was coupled to ErbB3 and could activate AKT only in cell lines that
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are sensitive to gefitinib. Gefitinib binds the EGFR/ErbB3 complex and inhibits PI3K
association therefore decreasing AKT activity. The association of ErbB3 and PI3K is not
seen in resistant cell lines and allows AKT to remain active as it is not inhibited when
gefitinib binds the ErbB dimer (Engelman et al., 2005). The receptor c-Met (MNNG HOS
transforming gene) is overexpressed in NSCLCs that are resistant to EGFR inhibitors.
c-Met also plays a role in breast cancer resistance to EGFR TKIs, as it was found to
activate EGFR substrates in the presence of EGFR inhibitors (Mueller et al., 2010;
Mueller et al., 2008). AKT is also activated through overexpression of c-Met in lung
cancer (Engelman et al., 2007). Ubiquitination is known to mediate resistance to
cetuximab as decreased receptors on the cell membrane still elicit a strong EGFR
signaling response and ubiquitin levels can determine receptor recycling or degradation
(Lu et al., 2007; Wheeler et al., 2008). IGFR-1 (insulin-like growth factor receptor 1)
activation is also shown to mediate resistance to EGFR inhibitors through activation of
AKT and P70S6K (Chakravarti et al., 2002). Epithelial to mesenchymal transition (EMT)
plays a role EGFR inhibitor resistance as mesenchymal type cells rely minimally on
EGFR signaling (Wheeler et al., 2010). While EGFR inhibitors are used in the clinic,
many studies have found a variety of mechanisms in vitro allowing the cell to
compensate for EGFR inhibition leading to resistance. These studies can allow
researchers and physicians to further explore combination therapies of EGFR inhibitors
and a drug that targets one of the known mechanisms of resistance.
1.3 PI3K/AKT/mTOR
AKT/PKB has been implicated in a variety of processes that lead to
tumorigenesis (Faivre et al., 2006; Fresno Vara et al., 2004). Hannahan and Weinberg
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designated six different hallmarks of cancer and AKT is involved in all. (1) Growth signal
autonomy: AKT overexpression or activation leads to signaling with a low amount of
growth factors, (2) Insensitivity to antiproliferative signals: Recruits Mdm2 (mouse
double minute 2 homolog) to the nucleus to inhibit p53, localizes p21Cip/Waf1 to promote
proliferation, and stabilizes Cyclin D1 to promote cell cycle progression, (3) Inhibition of
apoptosis: Inactivates Bad (Bcl-2-associated death promoter), procaspase-9, NF-ΚB
(nuclear factor kappa-light-chain-enhancer of activated B cells), and Fas ligand, (4)
Unlimited replicative potential: Phosphorylates hTERT (human telomerase reverse
transcriptase) to increase telomeres, (5) Angiogenesis: Promotes through eNOS
(endothelial nitric oxide synthase), (6) Invasion and metastasis: Inhibits anoikis and
stimulates MMP (matrix metalloproteinases) secretion to increase basement membrane
degradation (Fresno Vara et al., 2004).
AKT has three homologous isoforms (AKT1, AKT2, and AKT3) each with four
domains: a plekstrin homology (PH) domain, an N-terminal domain, kinase domain, and
a C-terminal domain (Alessi et al., 1996; Hay and Sonenberg, 2004). Full activation of
AKT requires phosphorylation of Thr308 and Ser473 through amino acid, glucose, and
oxygen and/or mitogen (hormone and growth factor) stimuli (Alessi et al., 1996;
Engelman, 2009). Activated AKT can then signal through the mTOR complexes by
binding to TSC2 and acting as a GAP (GTPase-activating protein) for the GTPase Rheb
(Hay and Sonenberg, 2004). Two complexes contain the mTOR protein, mTORC1
(mammalian target of rapamycin complex 1 [containing Raptor]) and mTORC2
(mammalian target of rapamycin complex 2 [containing Rictor]). Not much is known
about the regulation and function of mTORC2 but it contains 6 subunits; mTOR,
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Figure 5: mTOR is involved in multiple cellular processes.

	
  
mTOR is involved in many components of the cell. It signals for energy and protein
homeostasis within the cell. This figure is reproduced with permission from Yecies and
Manning, 2011.
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rapamycin-insensitive companion of mTOR

(Rictor), mammalian stress-activated

protein kinase interacting protein (mSIN1), protein observed with Rictor-1 (Protor-1),
mammalian lethal with Sec13 protein 8 (mLST8, also known as GbL), and DEP-domaincontaining mTOR-interacting protein Deptor (Laplante and Sabatini, 2009). Data
suggest that it phosphorylates the AGC kinase family, including AKT leading to a
feedback loop, protein kinase C alpha (PKCα), and the serum/glucocorticoid regulated
kinase 1 (SGK1) (Guertin and Sabatini, 2007). It also leads to actin regulation,
cytoskeleton formation and cell survival (Sarbassov et al., 2004). mTORC1 (known as
simply mTOR for the purposes of this dissertation) is involved in growth, proliferation,
autophagy, and translation (Ganley et al., 2009; Laplante and Sabatini, 2009). It is
comprised of five subunits: mTOR, regulatory-associated protein of mTOR (Raptor),
mLST8, proline-rich AKT substrate 40 kDa

(PRAS40), and (Deptor) (Laplante and

Sabatini, 2009).
mTOR activates P70S6K, which phosphorylates 4E-BP1 (eukaryotic translation
initiation factor 4E-binding protein 1) to remove it from eIF4E, (eukaryotic translation
initiation factor 4E) releasing the translation initiation factor allowing it to complex with
eIF4A (eukaryotic translation initiation factor 4A), and eIF4G (eukaryotic translation
initiation factor 4G) to form eIF4F (eukaryotic translation initiation factor 4F) and
stimulate translation. A more extensive review of translation initiation will follow in
Section 1.4. mTOR is also able to stimulate translation through phosphorylating eIF4B
allowing it to facilitate eIF4A helicase activity. Important tumorigenic proteins translated
through this mechanism are cell cycle regulating proteins, HIF-1α (hypoxia-inducible
factor 1-alpha), FGF (fibroblast growth factor), VEGF (vascular endothelial growth
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factor), STAT3 (signal transducer and activator of transcription 3), and c-Myc
(Strimpakos et al., 2009). mTOR is also involved in lipid biogenesis in the mitochondria
(Laplante and Sabatini, 2009; Schieke et al., 2006). Within the mitochondria, mTOR
affects mitochondrial membrane potential, oxygen consumption and cellular ATP levels
(Schieke et al., 2006). A complex signaling network activates mTOR and it can sense a
plethora of stimuli such as amino acids, mitogens, oxygen, stress, and inflammation to
generate a cellular response (Guertin and Sabatini, 2007; Hardie et al., 1998; Wouters
and Koritzinsky, 2008) (Figure 5).
Upstream of AKT is PI3K. The protein is a heterodimer comprising a catalytic
subunit (p110) and a regulatory subunit (p85) (Hay and Sonenberg, 2004). PI3K is
responsible

for

converting

phosphatidylinositol-4,5-bisphosphate

(PI-4,5-P2)

to

phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3). PIP3 then activates AKT through
the PH domain and phosphorylation by 3-phosphoinositide-dependent kinase-1 (PDK1).
The dephosphatase PTEN converts the second messenger, PIP3, back to the PIP2
form (Fresno Vara et al., 2004).
1.4 Protein Translation
All cells need the production of proteins for normal cellular functions. Cancer
cells have a larger requirement for proteins in order to maintain their high metabolic rate
and uncontrolled growth and proliferation. It was first observed that cancer cells have
larger and more numerous nucleoli, the location of ribosome assembly in 1976 (Gani,
1976). Scientists then found that translation is hyperactive in most cancer cells and the
proteins that control the process are often deregulated (Johnson et al., 1976; Silvera et
al., 2010). Due to the greater need for more numerous proteins in cancer cells, efforts
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are underway trying to target translational control in cancer. If the protein pool within the
cell could be decreased through inhibiting translation, then it is possible that the cell
would be unable to grow and proliferate even in the presence of tumorigenic stimuli due
to a lack of effector proteins. There are three steps in protein translation: initiation,
elongation, and termination. Most of the regulation occurs at the initiation step and
many drugs have been synthesized to target specific components of the process.
There are two types of translation: cap-dependent, which will be discussed immediately
below, and cap-independent, which will follow.
Cap-dependent translation is used for the synthesis of 95-97% of all proteins in
eukaryotes (Merrick, 2004). The name derives from the mRNA cap of a
guanine nucleotide attached to the mRNA via a 5′ to 5′ triphosphate bond. It requires
the eukaryotic initiation factors (eIFs). Translation initiation is controlled through the
eIF2, eIF3, and eIF4 families (Figure 6). Step 1 begins with the 80S ribosome
dissociating and binding to the ternary complex of a 60S ribosomal subunit, eIF3 and
eIF41A, and the 40S small ribosomal subunit. This 43S complex then binds with
methionyl tRNA (Met-tRNAi) as Step 2 (Gingras et al., 1999; Silvera et al., 2010). Step 3
is binding to the mRNA 5’ end through ATP hydrolysis and to the eIF4F complex
containing eIF4E, eIF4G, and eIF4A (Gingras et al., 1999; Merrick, 2004). The RNA
then binds the 43S complex as Step 4. eIF4B facilitates eIF4A helicase activity. Step 5
is the release of eIF4 family by a GTPase-activating protein (GAP), eIF5 and eIF2, and
scanning to find the AUG start codon as the 48S. In Step 6 all the initiation factors are
released and the 60S subunit joins the 40S and starts elongation as the 80S initiation
complex (Gingras et al., 1999; Merrick, 2004). At the end of initiation the 80S ribosome
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is attached to the start codon (Dever and Green, 2012). The second codon is in the A
site on the ribosome and a GTP is needed to attach the tRNA through the eukaryotic
elongation factor 1A (eEF1A). Elongation is the process of attaching all the aminoacyltRNA, which match with the RNA codons. The process repeats itself until reaching a
stop codon.
The codon recognizes its respective aminoacyl-tRNA then the hydrolyses of a
GTP moves the codon to the next site, P, in the ribosome leaving eEF1A to release and
allowing a peptide-peptide bond to form between the peptide in P, currently the start
codon and the A site (Dever and Green, 2012). eEF2 moves the peptides along to the E
and P sites and the A position opens with a new codon ready to attach to the tRNA. The
process continues until a stop codon UAA, UGA, or UAG. Termination requires the
factors eRF1 and eRF3. eRF1 recognizes the stop codon and causes peptidyl-tRNA
hydrolysis while eRF3 is a GTPase allowing for separation of the ribosome from the
newly synthesized peptide and RNA (Atkinson et al., 2008; Dever and Green, 2012).
Translation is a highly regulated process, which cancer cells often misregulate in
order to achieve the high number of proteins they require to sustain high metabolic
and proliferative rates. While translation initiation is the most regulated step in
translation and most drugs that target translation aim at the initiation factors, it is
important to understand the whole process of translation and how cancer is able to
exploit it. Ribosomal disorders are linked with an increased risk for developing certain
types of cancers (Loreni et al., 2013). Table 3 describes common ribosomal disorders,
the altered genes leading to the disease, and common cancers resulting from the
mutation. The most common cancers associated with ribosomal disorders include
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leukemias and lymphomas. For example, Diamond Blackfan anemia is associated with
an increased risk for many different types of cancer including MDS (myelodysplastic
syndrome), AML (acute myeloid leukemia), colon adenocarcinoma, osteogenic
sarcoma, and genital cancer. This disorder is characterized by mutations in many
ribosomal proteins (RPS), which comprise the 40S ribosome (Loreni et al., 2013). When
the 40S ribosome is improperly formed, it affects hematopoietic cell lineage resulting in
red blood cells that are immature and unable to properly bind iron leading to anemia
and an increased risk for leukemias (Boria et al., 2010). Cartilage hair hypoplasia is
another ribosome disorder that causes abnormal bone growth resulting in dwarfism.
Patients also have brittle and sparse hair, weak nails, and immune deficiency. In
comparison to Diamond Blackfan anemia, patients with Cartilage hair hypoplasia have a
deficiency in RMRP, which produces a noncoding RNA (Loreni et al., 2013). RMRP is
part of an enzyme complex called mitochondrial RNA-processing endoribonuclease, or
RNase MRP. RNase MRP is thought to be involved in mitochondrial DNA replication
and process ribosomal RNA. These patients often develop Non-Hodgkin’s lymphoma
and basal cell carcinoma along with gastrointestinal problems including celiac disease
(Hermanns et al., 2005).
Cap-independent translation (internal ribosome entry site; IRES) does not require
the use of the eIF4G mediated RNA binding cap (Silvera et al., 2010). Some mRNAs
have IRES sequences where the translation initiation factors can bind without the help
of the highly regulated eIF4F complex (Barna et al., 2008). Some of the mRNAs that
contain the IRES are involved in tumor progression and metastasis including vascular
endothelial growth factor A (VEGFA), fibroblast growth factor 2 (FGF2), BCL-2, X-linked
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inhibitor of apoptosis (XIAP), and HIF-1α (Braunstein et al., 2007). IRES-mediated
translation can also confer resistance to radiation through upregulation of the
antiapoptotic protein XIAP (Holcik et al., 2000). BCL-2 and XIAP are upregulated during
chromosomal instability caused by radiation and chemotherapy, and can support cancer
development, leading to drug resistance and increased tumorigenesis (Silvera et al.,
2010). Translational control is important in regulating cellular proteins that can support a
proliferative phenotype.
1.4.1 eIF4
Important to this dissertation is the eIF4 family of initiation factors and their role in
regulating translation. As mentioned above they are required for cap-dependent
translation. There are six members in the eIF4 family eIF4A, eIF4A1, eIF4B, eIF4E,
eIF4G, and eIF4H. eIF4A and eIF4A1 are helicases that are responsible for unwinding
the mRNA during translation (Parsyan et al., 2011). eIF4B, a major protein of interest in
this dissertation, facilitates eIF4A helicase activity making it much more efficient and
promotes the interaction of mRNA-rRNA-Met-tRNAi at the start codon (Gingras et al.,
1999). eIF4E has been the subject of extensive investigation (Gingras et al., 1999;
Wendel et al., 2004). It is considered an oncogene and is the rate limiting protein and
step in translation initiation. eIF4E is often sequestered by 4E-BP1 rendering it inactive
and only when 4E-BP1 is phosphorylated by activated mTOR does eIF4E release and
allow it to bind to eIF4G and eIF4A to form the eIF4F complex binding it to the mRNA
and starting translation initiation (Gingras et al., 1999; Wendel et al., 2004). eIF4G is a
scaffolding protein for the eIF4F complex and eIF4H has similar homology to eIF4B but
little is known about its function (Gingras et al., 1999).
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Figure 6: Cap-dependent translation initiation.

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  

	
  
The eIF4 family is required to assemble the translation initiation complex in
cap-dependent translation. Translation is comprised of three steps; initiation,
elongation, and termination. Cap-dependent translation requires the eIF4
family including eIF4B while cap-independent does not. Figure reproduced
with permission from Merrick, 2004.
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Table 3: Ribosomal disorders linked to cancer.	
  
Disease

Altered
gene

Cancer Association

Diamond Blackfan
anemia

RPS
7,10,17,
19,24,26
,RPL5,
11, 35A
DKC1

MDS, AML, colon
adenocarcinoma,
osteogenic sarcoma,
genital cancer

RPS14
SBDS

AML
MDS, AML

RMRP

Non-Hodgkin
lymphoma, basal cell
carcinoma

X-linked
dyskeratosis
congenita
Sq-syndrome
ShwachmanDiamond
syndrome
Cartilage hair
hypoplasia

AML, head and neck
tumors

Many ribosomopathies confer an increased risk for developing cancer. Aberrant
translation can lead to abnormal amounts of available protein within the cell
leading to increased proliferation and genetic instability. Abbreviations: AML,
acute myeloid lymphoma; MDS, myelodysplastic syndrome. Table reproduced
with permission from Loreni et al., 2013.
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eIF4B is important in the translation initiation process. While it is not the ratelimiting step or considered an oncogene like eIF4E, it is responsible for the efficiency of
the eIF4A helicase and is important to translation initiation (Gingras et al., 1999;
Shahbazian et al., 2010b). eIF4B is phosphorylated by two kinases on Ser422, P70S6K
and P90RSK (90kDa ribosomal s6 kinase, RSK) (Raught et al., 2004). P70S6K is
directly activated through mTOR while P90RSK is activated downstream of EGFR and
the MAPK cascade (Serra et al., 2013). eIF4B seems to be a point of convergence
between EGFR and mTOR further giving evidence to a complex network of signaling
cascades (Raught et al., 2004). The extensive crosstalk gives further validation that
multiple pathways must be inhibited for cancer to respond to treatment.
1.4.2 Ribosomal S6 Kinases
P70S6K is a serine/threonine kinase that is phosphorylated by mTOR and has
two homologs, S6K1 and S6K2 (Shima et al., 1998). It is a major protein in mTOR
control of translation through activating required proteins including elongation factors,
and poly(A)-binding protein (PABP) (Meyuhas, 2000). It also phosphorylates ribosomal
protein S6 (rpS6), tumor suppressor protein PDCD4, eIF4B, and translation elongation
factor eEF2 kinase (Korets et al., 2011). The kinase therefore plays a role in both the
translation initiation and elongation stages. One of the most extensively studied proteins
activated by P70S6K is rpS6. Knockout studies in vitro and in vivo demonstrate that the
protein, a member of the 40S ribosomal subunit, is important in binding the mRNA to
tRNA between the large and small ribosome (Nygard and Nilsson, 1990). Also of note,
eIF4B is activated by P70S6K and P90RSK in response to a multitude of extracellular
stimuli, which promote cell growth and proliferation such as serum, insulin, and phorbol
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esters (Duncan and Hershey, 1985). rpS6 and eIF4B are two examples of proteins that
demonstrate the extensive crosstalk between signaling pathways within the cell. They
are regulated by both the mTOR and MAPK pathways and therefore can detect signals
from a wide range of inputs.
P90RSK is a kinase that is directly phosphorylated by MAPK downstream of the
Ras-MAPK pathway and therefore EGFR. It has a similar motif to S6K and AKT
phosphorylating proteins with a basophilic motif RxRxxS/T (R, arginine; S, serine; T,
threonine; and x, any amino acid) (Manning and Cantley, 2007). The similar motif
explains the crosstalk mentioned above. P90RSK is also capable of activating rpS6 at
Ser235/236 and eIF4B at Ser422 independent of mTOR activity, opening the door for
EGFR control of translation through recruitment of the initiation complex (Roux et al.,
2007). Another example of P90RSK and mTOR crosstalk is the ability of P90RSK to
phosphorylate TSC2 thereby inactivating it and modulating mTOR activity (Roux et al.,
2004).
P90RSK has four isoforms in mammals RSK1-4 which are activated by
extracellular signal-regulated kinase-1 and -2 (ERK1/2) in response to many
extracellular signals including growth factors, hormones, neurotransmitters, and
chemokines (Chen et al., 1992). RSK1 and 2 are known to be activated in breast cancer
(Clark et al., 2005). RSK contains kinase domains, a linker region, and N- and Cterminal tails (Anjum and Blenis, 2008). The N-terminal kinase is homologous to ACG
family kinases including PKA, PKG, and PKC and phosphorylates substrates, while the
C-terminal domain is similar to the calcium/calmodulin-dependent protein kinases and is
responsible for the auto-phosphorylation ability of RSK (Bjorbaek et al., 1995; Fisher
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and Blenis, 1996). P90RSK is primarily activated by EGFR through the Ras-MAPK
cascade but it can also be activated by p38 MAPK, the ERK5 MAPK and fibroblast
growth factor receptor-3 (FGFR3) (Anjum and Blenis, 2008).
P90RSK is involved in translation as mentioned above through phosphorylation
of rpS6 and eIF4B but is also plays a role in transcriptional regulation, cell-cycle
regulation, and cell survival (Roux and Blenis, 2004). P90RSK is known to activate
transcription factors including CREB, ERα, NF-κB, and transcription initiation factor
TIF1A (Frodin and Gammeltoft, 1999; Roux and Blenis, 2004). It also regulates Fos and
Jun and through CREB regulation, P90RSK also controls Signal transducer and
activator of transcription 3 (STAT3) activation (Anjum and Blenis, 2008; Chen et al.,
1993). P90RSK has a hand in cell survival through the phosphorylation and inactivation
of Bad, disabling Bad’s ability to inhibit the pro-survival protein, BCL-XL (Shimamura et
al., 2000). P90RSK also controls cell cycle progression through regulating p27, a cyclindependent kinase inhibitor, allowing G1 progression (Anjum and Blenis, 2008). G2-M
phase also is regulated through P90RSK and its ability to inhibit Myt1 kinase allowing
progression into meiosis as demonstrated in Xenopus laevis oocytes (Palmer et al.,
1998).
1.5 STAT3
STAT3 is a transcription factor that can be activated by a variety of signaling
proteins including membrane receptors, i.e., EGFR, and other kinases, i.e., mTOR
(Figure 7). The STAT family has seven members including STAT1, STAT2, STAT3,
STAT4, STAT5a, STAT5b, and STAT6 (Quesnelle et al., 2007). Janus kinases (JAKs)
are intermediary kinases that often activate STATs. Cell surface receptors such as

	
  

	
  

37	
  
	
  
PDGFR,

EGFR,

and

FLT3

can

activate

the

transcription

factors

through

phosphorylation. They can also be activated through non-receptor protein tyrosine
kinases such as c-Src, Bcr-Abl, and mTOR (Buettner et al., 2002). Once activated,
STATs dimerize and translocate to the nucleus where they recruit cofactors to then bind
the DNA at STAT3 specific binding sites resulting in transcription. The wide range of
interacting proteins and different mechanisms of activation demonstrate the broad
network to which the transcription factors are connected.
While most is known about STAT5 and STAT3 as they are associated with
cancer, the STAT family shares common features (Buettner et al., 2002). Once
phosphorylated STATs can either homo- or heterodimerize and translocate to the
nucleus where they exert their control on gene expression (Furqan et al., 2013). Each
STAT is transcribed by a separate gene but they have six conserved domains: an Nterminal oligomerization domain, a coiled coil, a DNA binding domain, a linker domain,
an SH2 domain, and a C-terminal transactivation domain (Furqan et al., 2013).
STAT2, 4, & 6 are known to regulate immune response while STAT1, 3, and 5 are
involved in cell cycle, survival and angiogenesis (Furqan et al., 2013).
STAT3 is often considered an oncogene due to its ability to drive tumor formation
in mice when constitutively activated (Bromberg et al., 1999). STAT3 has been
implicated in cancer progression for many years and is the most researched member of
the STAT family. Its overexpression has been found in lung, gastric, breast and
colorectal cancers and is associated with a poor prognosis (Haura et al., 2005; Kusaba
et al., 2005; Sheen-Chen et al., 2008; Yakata et al., 2007). STAT3 is involved in cell
cycle regulation through activation of transcription of CyclinD1, CyclinD3, c-Myc,
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p21waf1, and p27, angiogenesis through VEGF, and invasion and metastasis through
MMP-2 and MMP-9 (Furqan et al., 2013; Quesnelle et al., 2007). STAT3 target genes
also include anti-apoptotic genes such as Survivin, Mcl-1, and

Bcl-XL (Leeman et al.,

2006). There is significant overlap between the genes whose transcription is regulated
by STAT3 and STAT5. STAT5 also mediates c-Myc, CyclinD1, CyclinD2, and Mcl-1
transcription (Page et al., 2012). Conversely, STAT1 has not been linked to tumor
progression but might be a tumor suppressor and activates transcription of similar
proteins involved in cell survival (Chan et al., 2004; Ferbeyre and Moriggl, 2011;
Watanabe et al., 2001) (Table 4).
The oncogenic potential of STAT3 is through its control of important cell cycle
regulators leading to cell cycle progression, survival, and malignant progression
(Bowman et al., 2000). Figure 8 shows how STAT3 plays a role in many of the
Hannahan and Weinberg hallmarks of cancer. STAT3 is involved in 1. Inhibiting
apoptosis: regulation of BCL-XL and survivin, 2. Cell cycle activation: Myc, CyclinD1,
and Cdc25A, 3. Telomere length: upregulation of telomerase, 4. Metastasis: MMP-9, 5.
Angiogenesis: VEGF. Many drugs have been developed to control STAT3 signaling.
STATTIC (STAT Three Inhibitory Compound), a drug used in this project was the first
non-peptide small molecule inhibitor for STAT3. It works by obstructing the dimerization
of the transcription factor and therefore prevents its activity. It has been studied in a
variety of cancers including breast, hepatocellular carcinoma, pancreatic, colon,
glioblastoma, and multiple myeloma (Furqan et al., 2013).
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Figure 7: STAT3 signaling pathway.

	
  
	
  
	
  
STAT3 is a transcription factor that can be activated by a variety of signaling cascades
including EGFR and mTOR. This figure is reproduced with permission from Cell
Signaling.
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Table 4: STAT activation in tumors.

Solid tumor
type
Breast

STAT
activation
STAT1, STAT3,
STAT5
Head and neck STAT1, STAT3,
STAT6
Lung
STAT3, STAT5
Prostate
STAT3
Colon
STAT3
Glioma
STAT3
Melanoma
STAT3
Ovarian
STAT3
Pancreatic
STAT3
Renal
STAT3
Liver
STAT3

STATs are activated in a variety of
solid tumors, most frequently STAT3
and STAT5. Table reproduced with
permission from Quesnellle et al.,
2007.
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STAT3 is phosphorylated on two residues required for full activation, Tyr705 and
Ser727. Of particular note, in relation to this dissertation, is that STAT3 can bind to the
EGFR and be phosphorylated on Tyr705 through EGFR sites Y1086 and Y1068, and
mTOR on Ser727, which increases the transcription activity (Quesnelle et al., 2007).
One interesting article noting the crosstalk between EGFR, mTOR, and STAT3 found
that when all three proteins are upregulated in gastric cancer, there is a significant
correlation with higher tumor stage, lymph node involvement and invasion (Inoki et al.,
2005; Inokuchi M et al., 2011). The combination of EGFR and mTOR inhibitors was
found to decrease tumorigenesis in GBM cell lines through inhibition of STAT3
phosphorylation (Rajan et al., 2003). The ability of EGFR and mTOR to converge upon
STAT3 in different types of cancer suggests that the drug combination of EGFR and
mTOR inhibitors should further be explored in combination for their ability to inhibit pSTAT3.
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Figure 8: STAT3 is involved in tumorigenesis.

	
  
	
  
STAT3 is involved in many aspects of tumorigenesis leading to a decrease in apoptosis,
and an increase in replicative potential, metastasis, and angiogenesis. Figure is
reproduced with permission from Barre et al., 2007.
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CHAPTER 2: Exploring Resistance Pathways to EGFR Inhibitors
2.1 Hypothesis and Specific Aims
The overall hypothesis for the project described in this dissertation is that mTOR
inhibition can sensitize TNBC cells to EGFR TKIs through the inhibition of eIF4B and
STAT3 phosphorylation. To test this hypothesis we addressed three specific aims:
Aim I: To determine the effect of abrogating both EGFR and mTOR
signaling on growth and survival in TNBC cell lines. The working hypothesis
for this aim is that the combination of mTOR and EGFR inhibitors abrogates cell
growth and colony formation in TNBC cells.

We tested this hypothesis by

measuring the effect of temsirolimus and gefitinib on cell growth, colony
formation, and viability using BT20, MDA-MB-231, and MDA-MB-468 TNBC
cells. We also determined the mechanism by which viability is decreased by
measuring apoptosis, autophagy, and cytostasis.
Aim II: To investigate the role eIF4B plays in the synergistic effect of EGFR
and mTOR dual inhibition in TNBC cell lines. The working hypothesis for this
aim is that the phosphorylation of eIF4B represents a common mediator of
survival in TNBC and that this phosphorylation needs to be abrogated to
decrease cell growth. To test this hypothesis we used siRNA and small molecule
inhibitors to decrease eIF4B phosphorylation and expression. We also
investigated the role of the two kinases responsible for phosphorylating eIF4B,
P70S6K and P90RSK. Finally, we determined the significance of cap-dependent
versus cap-independent translation in the mediation of cell survival in TNBC cell
lines.
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Aim III: To identify the role of STAT3 in the treatment of TNBC cell lines
with EGFR and mTOR inhibitors. The working hypothesis for this aim is that
STAT3 phosphorylation is co-regulated by EGFR and mTOR signaling and that
inhibition of STAT3 phosphorylation is required for efficacy of the combination of
gefitinib and temsirolimus. To test this hypothesis we abrogated STAT3
activation and phosphorylation using an established small molecule inhibitor,
STATTC. We also constitutively activated STAT3 through plasmid transfection
(Stat3c) to determine if STAT3 phosphorylation is a common mediator for EGFR
and mTOR signaling.
We think the studies proposed here outlined EGFR and mTOR inhibitors as an effective
in vitro combination that warrants further investigation in the treatment of TNBC. In
addition, these studies defined the eIF4B and STAT3 signaling pathways as activated
by EGFR and mTOR that need to be abrogated to mediate the synergistic effects of
gefitinib and temsirolimus treatment. Clinically, many women who develop TNBC
ultimately fail treatment and therefore better drug regiments need to be developed.
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CHAPTER 3: Materials and Methods
3.1 Human Breast Cancer Cell Lines and inhibitors
Gefitinib (Iressa) was provided by AstraZeneca (London, UK). Temsirolimus was
purchased from LC Labs (Woburn, MA, USA). STATTIC was purchased from Abcam
(Cambridge, UK). BI-D1870 and AT7867 were purchased from Selleck Chemicals
(Boston, MA, USA). MDA-MB-231, MDA-MB-468, and BT20 cells were purchased from
ATCC (Manassas, VA, USA). HEK293T cells were purchased from Invitrogen
(Carlsbad, CA, USA). MDA-MB-231, MDA-MB-468, and HEK293T cells are grown in
DMEM+10% FBS media (Dulbecco's modified Eagle's medium supplemented with 10%
Fetal Bovine Serum). BT20 cells are grown in Eagle’s + NEAA media (Eagle's MEM
[Minimum Essential Medium] with 2 mM L-glutamine and Earle's Balanced Salt Solution
adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids,
1 mM sodium pyruvate, and 10% FBS). All other reagents were purchased from Thermo
Fisher (Houston, TX, USA) or Sigma (St. Louis, MO, USA), unless indicated. A genomic
profile of the cell lines with common mutations can be found in Supplemental Table 2.
3.2 Phospho Mass Spectrometry
The Mass Spectrometry methods were generated by Dr. Paul Stemmer and can
be found in a recently submitted manuscript with the title “Abrogating phosphorylation of
eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast
cancer” of which he is a co-author with the author of this dissertation work and in
Supplemental Methods. The samples were prepared under the guidance of Dr.
Stemmer by J. Madden after which he took control of the samples for further analysis.
Methods that this author performed are included.
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BT20 cells were treated with 0.5 µM gefitinib or a DMSO vehicle control for 24
hours. Cells were washed with ice-cold HANK’s solution then proteins precipitated with
100% EtOH before cell proteins were scraped from plates and transferred to
microcentrifuge tubes. Samples were then taken to the Proteomics Core and further
analysis was performed by Dr. Paul Stemmer. Experiment was done two times with the
first experiment containing 14 samples per treatment and the second containing 4
samples.
3.3. Ingenuity® Pathways Analysis
The methods were performed by Dr. Aliccia Bollig-Fischer for a recently
submitted manuscript with the title “Abrogating phosphorylation of eIF4B is required for
EGFR and mTOR inhibitor synergy in triple-negative breast cancer” of which she is a
co-author with the author of this dissertation work. As the author of this work did not do
the bioinformatics work, detailed methods have been excluded.
3.4 Cell Viability Assays
Cells were plated in triplicate at 2,000 cells /well of a 96-well plate on Day 0.
Cells were treated with 0.001 µM, 0.01 µM, 0.1 µM, 1 µM, 10 µM, 20 µM, and 50 µM
gefitinib and/or temsirolimus, BI-D1870 and/or AT7867, and STATTIC on Day 1. The
MTS reagent was added per manufacturer’s directions after 72 hours (Day 5)
(Promega, Madison, WI, USA) and was read using a Dynex spectrophotometer.
GraphPad Prism was used to generate GI50 curves at inhibitory growth curves with
top=1 and bottom=0. GI50 values were generated by the program from the data of at
least three experiments performed in triplicate.
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3.5 Cell Growth Analysis
Cells were plated in triplicate at 30,000/ well of a 6 well plate on Day 0.
Treatment with gefitinib (1 µM), temsirolimus (1 µM), BI-D1870 (10 µM), AT7867 (10
µM), alone or in the combinations specified in the text began on Day 1 and continued
every other day for 8 days.

Day 1 untreated cells were counted using a

hemocytometer. On Days 4 and 8 the respective plates were counted again using a
hemocytometer. Experiments were repeated at least three times. Graphs were prepared
and statistical analysis was performed in GraphPad Prism (La Jolla, CA, USA) using an
ANOVA.
3.6 Clonogenic Survival Assays
BT20 cells (40,000 cells/ 35-mm dish) or MDA-MB-231 and MDA-MB-468 cells
(30,000 cells/ 35-mm dish) were plated on Day 0. Cells were treated with gefitinib ([1
µM BT20] [10 µM MDA-MB-231 and MDA-MB-468]) and/or temsirolimus ([1 µM BT20]
[10 µM MDA-MB-231 and MDA-MB-468]) as specified in the text. Treatment began on
Day 1 and continued every other day for 10 days. On day 10, cells were trypsinized and
replated at 5,000 cells/ 35-mm dish (BT20) or 3,000 cells/ 35-mm dish (MDA-MB-231
and MDA-MB-468) without treatment for 7 days. Different plating densities allowed for
the longer doubling time in BT20s compared to MDA-MB-231 and MDA-MB-468, which
replicate more quickly. Colonies were stained with crystal violet for 20 minutes, washed
with water to remove excess dye, and counted using the Gelcount colony counter the
following day (Oxford Optromix; Abingdon, United Kingdom). Counts were normalized to
the untreated control for each experiment. Experiments were done in triplicate and
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repeated at least three times. Graphs were prepared and statistical analysis was
performed in GraphPad Prism using an ANOVA.
3.7 Immunoblotting
Cells were lysed in CHAPS lysis buffer (10 mM CHAPS, 50 mM Tris [pH 8.0],
150 mM NaCl, and 2 mM EDTA with 10 µM Na3VO4 and 1x protease inhibitor cocktail
[EMD Biosciences, Rockland, MA]) at 4°C. Proteins were separated using sodium
dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) 7.5% or 12% gel and
transferred onto polyvinylidene fluoride (PVDF) membranes for 1 hour at 23V. Blots
were blocked in 5% milk or 5% BSA according to manufacturer’s instructions and then
were placed in primary antibody overnight at 4°C shaking, washed with TBS-T for 10
minutes x3, and incubated with secondary antibody for 1 hour at room temperature.
After secondary antibody incubation, blots were washed with TBS-T for 10 minutes x3
and developed using Amersham ECL Prime Western Blotting Detection Reagent
solution (GE Healthcare, Amersham, United Kingdom). Relevant antibodies can be
found in Table 4. Antibodies used in this study were purchased from Cell Signaling
Technologies (Beverly, MA, USA), BioSouce (Grand Island, NY, USA), or Millipore
(Billerica, MA, USA).
3.8 siRNA silencing
siRNA constructs were purchased from Thermo Scientific Dharmacon®.
Constructs to eIF4B are non-overlapping and described as #7 (catalog number J020179-07 sequence 5’ AAACCUACCCUAUGAUGUU 3’) and #8 (catalog number J020179-08 sequence 5’ GCAGUGCGUUUACCACGUG 3’) in the text. Non-silencing offtarget siRNA (non-silen) was used as a control (catalog number D-0018810-01-05).
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Plates were treated with 0.7 µg/ well siRNA (96 well) or 2.5 µg siRNA / well (6 well)
siRNA using the Lipofectamine LTX transfection system. siRNA was combined with
Lipofectamine LTX and PLUS in Opti-MEM supplemented with antibiotic free growth
media to a final volume (96 well LTX 0.3 µL, PLUS 0.01 µL, 6 well LTX 2 µL, PLUS 0.5
µL).
3.9 Bicistronic luciferase Assay
A dual luciferase plasmid was purchased from Addgene (Cambridge, MA, USA).
HEK293T cells were transfected with 11510:pFR_HCV_xb (Supplemental Figure 2).
After 24 hours, media were removed and replaced with media containing gefitinib and/or
temsirolimus at 1 µM. Cells were then harvested after an additional 24 hours and
luciferase activity was measured using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI, USA) and read using the BioTek Synergy 2 machine
(Winooski, VT, USA) according to the manufacturer’s instructions. Relative luciferase
units were plotted in GraphPad Prism as normalized firefly (cap-dependent translation)
over normalized renilla (cap-independent translation).
3.10 Stat3c plasmid
The EF.STAT3C.Ubc.GFP plasmid (Stat3c) to express constitutively activated
STAT3 was purchased from Addgene, plasmid number 24983 (Hillion et al., 2008).
Cells were treated with 1 µg/well plasmid DNA (96 well) or 1.5 µg DNA/well (6 well)
using the Lipofectamine LTX transfection system. Stat3c was combined with
Lipofectamine LTX and PLUS in Opti-MEM supplemented with antibiotic free growth
media to final volume (96 well LTX 0.3 µL, PLUS 0.08 µL, 6 well LTX 3 µL, PLUS 1 µL)
and harvested or read through MTT cell viability assay after 72 hours.
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3.11 STAT3 DNA Binding ELISA
The STAT3 Transcription Factor Assay Kit (catalog number 45696) was
purchased from Active Motif (Carlsbad, CA, USA). Protocol was followed according to
manufacturer’s instructions. Briefly, the kit detects and quantifies the transcription factor
activity when active STAT3 in the sample binds to a STAT3 consensus sequence that is
bound to the kit plate (5’ TTCCCGGAA 3’). A STAT3 primary antibody detects the
STAT3 bound to the plate containing the STAT3 consensus site and a secondary HRPconjugated antibody provides a colormetric readout that is then quantified using
spectrophotometry. 10 µg of cell lysate was used for each assay. Experiments were
repeated at least two times. Treatments were 1 µM of the indicated drug for 24 hours.
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Table 5: Relevant antibody information.
	
  
Target
AKT
Caspase 3
Caspase 7
Caspase 9
Cleaved Caspase 3
Cleaved Caspase 7
Cleaved Caspase 9
EGFR
eIF4A
eIF4A1
eIF4B
eIF4E
eIF4G
eIF4H
Anti-mouse IgG HRP linked
Anti-rabbit IgG HRP linked
LC3*
MAPK
P21Waf1*
P38
P53
P70S6K
phospho-AKT (Ser473)
phospho-EGFR (Thr669)
phospho-EGFR (Tyr1045)
phospho-EGFR (Tyr1068)
phospho-EGFR (Tyr1086)
phospho-EGFR (Tyr1173)
phospho-EGFR (Tyr845)
phospho-EGFR (Tyr992)
phospho-eIF4E (Ser209)
phospho-eIF4G (Ser1108)
phospho-MAPK (Thr20/Try204)
phospho-P38 (Thr180/Tyr182)
phospho-P70S6K (Thr389)
phospho-P90RSK (Ser380)
phospho-PKCpan
phospho-STAT3 (Y705)*
phospho-STAT3 (S727)
RSK1/2/3
β-actin*

Company
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Millipore
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
BioSource
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Sigma

Catalog number
9272
9665
9494
9508
9501
9491
9664
2232
2013
2490
3592
2067
2469
2444
7076
7074
4599
9102
2946
9212
OP09
2708
4060
3056
2237
2234
2220
4407
2231
2235
9741
2441
44-680g
9211
9205
9335
9371
9138
9134
9355
A5441

Dilution used
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:2000
1:1000
1:1000
1:2000
1:1000
1:1000
1:2000
1:2500
1:1000
1:500
1:5000
1:500
1:500
1:750
1:500
1:1000
1:2000
1:2000
1:500
1:1000
1:500
1:1000
1:500
1:1000
1:500
1:10000

Antibodies used in this work were purchased from Cell Signaling, BioSource, or
Millipore. Catalog numbers and concentrations used are provided. All antibodies are
used with secondary rabbit HRP-linked IgG unless noted with * indicating use of mouse
HRP-linked IgG.
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CHAPTER 4: Identification of proteins remaining phosphorylated after gefitinib
treatment in TNBC
4.1 Introduction
As previously mentioned 50% of TNBC patient tumors express high levels of
EGFR but are resistant to inhibitors (Liu et al., 2011). EGFR inhibitors are approved in
the clinic for colon and NSCLC but have proven ineffective for breast cancer due to high
levels of developed and de novo resistance. Therefore, they are not used as a single
agent therapy but are given in combination with cytotoxics (Chong and Janne, 2013).
An emerging technology is the use of proteomics to better understand complex
signaling networks within the cell. The therapeutic potential of phospho-proteomics is
rapidly advancing (Lopez et al., 2012). Since many signaling proteins are considered
active based on the presence or absence of a phosphate(s) group (PO43-), phosphoproteomics is an excellent tool to study protein activation on a massive scale.
Interpreting the data through bioinformatics can then allow for identification of important
signaling pathways specific for the samples. Other phospho techniques, such as
antibody detection of protein levels through immunoblotting are limited in their ability to
identify only one protein at a time, but phospho-mass spectrometry is able to detect and
measure the phosphorylation of tens of thousands of proteins simultaneously. Mass
spectrometry based assays can assist in drug development through (i) clarification of
the mechanism of drug action, (ii) identification of proteins related to a signaling
network, (iii) discovering novel drug targets for diseases (Lopez et al., 2012; Lopez et
al., 2011). While phospho-proteomics can be a good tool to identify drug targets, it also
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has promise to be used on a patient level to diagnose and better understand the
individual disease and help predict treatment response (Lopez et al., 2012).
Phospho-mass spectrometry is able to capture and identify proteins based on the
presence of the phosphate group. Once proteins have been precipitated in ethanol, they
are digested, run through a titanium dioxide (TiO2) column to select for peptides
containing a phosphate. TiO2 was used as the selecting agent in this work as it is able
to select proteins phosphorylated at serine, tyrosine, and threonine sites, therefore,
giving a complete profile of the phospho-proteome (Chen and Chen, 2005). The
phosphorylated proteins are then identified through mass-spectrometry.
4.2 Results
4.2.1 Summary of proteins remaining phosphorylated in the presence of gefitinib
In order to identify potential mechanisms of resistance to EGFR inhibitors in
TNBC, we utilized a phospho-proteomics approach. We treated the TNBC cell line,
BT20 with gefitinib, an EGFR TKI and performed Phospho Mass Spectrometry with the
help of the Proteomics Core at Wayne State and Dr. Paul Stemmer. BT20s were
chosen for their TNBC status, high levels of EGFR, and intrinsic resistance to EGFR
TKIs. Briefly, after 24 hours treatment with gefitinib or a vehicle treated DMSO control,
proteins were harvested in ethanol. The samples were then sent to the Proteomics Core
where they were lysed in deoxycholate and digested in trypsin. The phospho-peptides
were enriched at all three phosphosites, tyrosine, serine, and threonine using TiO2. The
Proteomics Core was able to identify 279 proteins whose phosphorylation statues did
not significantly change in the presence of gefitinib. All identified proteins can be found
in Supplemental Table 1.
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4.2.2 mTOR signaling remains activated in the presence of EGFR inhibitors in
TNBC
With the help of the Bioinformatics Core and Dr. Aliccia Bolig-Fischer we utilized
Ingenuity® Pathway Analysis to interpret the phospho-proteomic data. Bioinformatics
are a useful tool to identify commonalities within a data set and have been used in many
studies to discover relevant signaling pathways from a library of proteins. The analysis
found many pathways containing multiple proteins that remained activated after gefitinib
treatment. The top scored pathways are found in Table 6. Molecular transport, RNA
trafficking, and protein synthesis had the highest number of associated proteins. This
analysis also led us to discover many of the phosphorylated proteins from the proteomic
data are involved in the mTOR pathway, particularly translation initiation (Table 7).
4.3 Conclusions
mTOR is often activated in many types of cancer and has been studied in
relation to resistance to EGFR inhibitors (Buck et al., 2006; Wheeler et al., 2008). EGFR
and mTOR pathways have been implicated in cancer progression and linked as having
extensive crosstalk for many years (La Monica et al., 2009; Rini et al., 2007). Therefore,
the bioinformatics data led us to further explore the role of mTOR as a mechanism of
resistance in TNBC due to the high number of mTOR related proteins that remained
activated after EGFR inhibition.
Of note many proteins remained phosphorylated after gefitinib treatment in the
Mass Spec data as seen in the Supplemental Table 1. Many of these proteins fit into a
variety of pathways that we could have explored as mechanisms of resistance for this
project. mTOR is only one of what can be many other pathways that contribute to EGFR
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inhibitor resistance in TNBC. Many of the pathways related to mTOR had the top hits in
the proteomics data. eIF2, eIF4, and P70S6K had the most number of proteins involved
that fit into the pathway. However, other pathways were also enriched in high numbers
including Integrin signaling, RhoA, and CHK mediated cell cycle control. Phosphoproteomics are a good resource to identify pathways that can contribute to inhibitor
resistance and generate hypothesis driven research. It is a tool that can lead to
interesting pathways and proteins that otherwise would have remained undiscovered.
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Table 6: Ingenuity® Pathway Analysis Top Functional Scores.
Score
54
44
41
39
23
23

17
15

Focus Molecules Top Functions
27
Molecular Transport, RNA Trafficking, Protein Synthesis
Cardiovascular System Development and Function,
23
Organismal Development, Cellular Assembly and
Organization
Cell Cycle, DNA Replication, Recombination, and Repair,
22
Gene Expression
Cellular Compromise, Cellular Function and Maintenance,
21
Protein Synthesis
Infection Mechanism, Reproductive System Disease,
15
Cellular Assembly and Organization
Cellular Assembly and Organization, Cellular Function
14
and Maintenance, Nervous System Development and
Function
Cellular Development, Hematological System
11
Development and Function, Connective Tissue
Development and Function
Cellular Compromise, Cellular Growth and Proliferation,
10
Cellular Assembly and Organization

Ingenuity based pathway analysis sorted proteins based on the phospho-proteomic data
and scored the most commonly activated pathways. Analysis is based on proteomic
data from BT20 cells treated with 0.5 µM gefitinib compared to a DMSO vehicle control.
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Table 7: Proteins involved in translational control that remained phosphorylated
after gefitinib treatment involved in mTOR pathway.
Proteins involved in translational control that remained phosphorylated after
gefitinib treatment involved in mTOR pathway
Protein
Function in Translation
eIF1B
Enhance rate and accuracy of Translation
eIF3B
Step 1 of Translation initiation 40S subunit binding
eIF3D
Step 1 of Translation initiation 40S subunit binding
eIF3G
Step 1 of Translation initiation 40S subunit binding
eIF3J
Step 1 of Translation initiation 40S subunit binding
eIF3C
Step 1 of Translation initiation 40S subunit binding
eIF2A
Step 2 Bind initiator tRNA and 40S subunit
eIF4G1
Step 3 of Translation initiation activation and binding of mRNA to 40S
Raptor
Major subunit of mTORC1
Rictor
Major subunit of mTORC2
GSK3A
Glycogen synthase kinase
4EBP1
Directly binds and activates eIF4E- rate limiting step in Translation initiation
FKHR
Forkhead Transcription factor- glucose homeostasis, cell-cycle
(FOXO3) progression, and apoptosis
	
  
Cells were harvested in ice cold ethanol, lysed in deoxycholate, trypsin digested, and
phospho-peptides were enriched at tyrosine, serine, and threonine sites using Ti2O.
Phospho-mass spectrometry on BT20 cells showed 279 proteins remained activated in
the presence of 0.5 µM gefitinib. Ingenuity® based pathway analysis found many
components of the mTOR pathway and translation initiation factors to be of interest. A
complete list of phosphorylated proteins can be found in Supplemental Table 1.
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CHAPTER 5: EGFR and mTOR Inhibitor Synergy in TNBC
5.1 Introduction
TNBC cells with high levels of EGFR have an intrinsic resistance to EGFR TKIs.
Phospho-proteomic data indicated that the mTOR pathway may be responsible for
EGFR inhibitor resistance and suggest that inhibition of mTOR may circumvent this
resistance and sensitize cells to EGFR treatment. Rapamycin (sirolimus) was first
discovered in the soil of Easter Island as a macrolide antibiotic produced from
Streptomyces hygroscopicus and was used as an immune suppressant after patients
received organ transplants (Albert et al., 2010; Vezina et al., 1975). Analogs of the drug
have been developed, coined rapalogs, also inhibit mTOR.
5.2 Results
5.2.1 Inhibiting mTOR activity sensitizes TNBC cells to EGFR Inhibitors
In our studies we have chosen to use the mTOR inhibitor temsirolimus, which is
used in the clinic to treat renal cell carcinoma (Albert et al., 2010). MTT assays were
used to determine the GI50s of temsirolimus for the TNBC cell lines. The cell lines used
in this project were chosen due to their triple negative status, the fact that they contain
high levels of EGFR, and have an increased resistance to EGFR inhibitors (µM GI50
values, Table 8). As seen in Table 8, the temsirolimus GI50 values for the BT20, MDAMB-231, and MDA-MB-468 TNBC cell lines were all >9.5 µM, a value considered to
indicate resistance to mTOR inhibition.
We further used growth assays to determine the effect gefitinib and temsirolimus
had individually and in combination on TNBC cells. Cells were plated on Day 0, treated
on Day 1, and every other day until Day 8, with gefitinib, temsirolimus, or the
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combination at the indicated doses (Figure 9A).

On Days 1, 4, and 8, cells were

counted using a hemocytometer from triplicate wells and plotted using GraphPad Prism.
In support of the MTT GI50 data in Table 8, gefitinib (GEF) and temsirolimus (TEM) did
not have a significant effect on cell growth in any of the cell lines (Figure 9A, red and
green lines). However, the 1:1 combination of gefitinib and temsirolimus at 1 µM had a
significant decrease (p<0.01 for MDA-MB-231, and p<0.001 for BT20 and MDA-MB468) in cell growth over an 8 day period that was not seen with single agent treatment at
the same concentration in all cell lines (Figure 9A). There was also a significant
decrease in growth comparing GEF (red line) and GEF+TEM combination (blue line) in
all cell lines (p<0.05). EGFR and mTOR dual inhibition has a significant effect at
decreasing TNBC cell growth that is not observed with individual treatment. Both
gefitinib and temsirolimus are approved for the treatment of cancers. Using already
approved drugs in a new setting allows for easier study and transition into patients, as
the toxicity profile is known. FDA approval for drugs already in the clinic is much easier
if they show efficacy in a new disease. Therefore, it is a significant finding that our
studies found a synergistic effect at decreasing TNBC cell growth using approved
drugs.
Clonogenic survival assays were then utilized to analyze the ability of EGFR and
mTOR inhibitors to decrease cell survival over an extended period of time. The assay is
a way to look at resistance as the cells are grown with drug treatment for a 10 days,
replated and grown with normal growth media for another week to see if they were able
to recover from the drug treatment. An effective cancer treatment needs to efficiently
and permanently inhibit cell growth while circumventing resistance, a major problem for
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TNBC patients in the clinic. While single agent treatment with gefitinib and temsirolimus
had minimal effects at decreasing colony formation, the combination showed a
significant decrease (Figure 9B p*<0.05, **0.01, ***0.001, ****0.0001). One cell line,
BT20, had a significant decrease in colony formation when treated with single agent
temsirolimus treatment. Our results suggest that mTOR inhibition has a greater effect at
decreasing cell growth and colony formation than single agent EGFR inhibition but not
to the extent of the combination. Our data suggest that mTOR inhibition can sensitize
TNBC cells that are resistant to EGFR inhibitors and decrease cell growth and colony
formation.
5.2.2 EGFR and mTOR inhibitors are synergistic in TNBC
Other studies have found that EGFR and mTOR inhibitors in combination are
effective experimentally in NSCLC, pancreatic, colon and breast cancers (Buck et al.,
2006; Chacon and Costanzo, 2010). Our results demonstrate a significant decrease in
growth and colony formation with the combination treatment of gefitinib and
temsirolimus (Figure 9). As mentioned previously, MTT data on three TNBC cell lines
shows that they are resistant to single agent treatment of gefitinib and temsirolimus
(Table 8). The growth and colony assays suggest a combinatorial effect. Figure 10A
shows GI50 growth curves for all cell lines. The combination of gefitinib and temsirolimus
(GEF+TEM) shifts the curves to the left, indicating a lower GI50 value than with the
individual treatments alone. The raw MTT data were then used to evaluate the synergy
of the two drug combination using the Chou-Talalay method (Chou, 2006).
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Table 8: Gefitinib and temsirolimus GI50 and CI values in TNBC.

9.79 µM

GI50
GEF+TEM
0.94 µM

CI
value
0.21

>100 µM

>100 µM

4.1 µM

0.28

6.8 µM

16.4 µM

3.7 µM

0.56

Cell Line

GI50 GEF

GI50 TEM

BT20

5.3 µM

MDA-MB-231
MDA-MB-468

The GI50 values for each TNBC cell line were considered resistant for individual drug
treatments. The combinations had lower GI50 values for all cell lines and the CI values
were calculated using CalcuSyn. All CI values <1.0 indicate a synergistic effect with the
combination of gefitinib and temsirolimus in BT20, MDA-MB-231, and MDA-MB-468
cell lines.
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Using CalcuSyn software we calculated the GI50 value for each cell line and drug
from MTT assays done with increasing concentrations of gefitinib and temsirolimus at
constant ratios. The GI50 for each individual drug alone is plotted on a graph, gefitinib on
the Y-axis and temsirolimus on the X-axis (Figure 10B). By drawing a line between the
GI50 values and plotting the calculated drug concentration in the presence of the other
drug on the same graph (Figure 10B, triangles) for a given drug concentration, we can
observe synergy. Any points falling under the line indicate the drug combination is
synergistic. In all three cell lines, all points fall below the line indicating synergy. The
calculation of CI (combinatorial index) values was done to further confirm the synergy of
gefitinib and temsirolimus in TNBC cell lines (Table 8). CI values less than 1.0 are
another indicator of synergy and all cell lines had calculated CI values of less than 1.0.
Together, our data confirm what others have seen and suggest that EGFR and mTOR
inhibition results in a significant and synergistic decrease in cell growth and colony
formation in TNBC cell lines.
5.2.3 Cell death mechanism
The synergy observed with the gefitinib and temsirolimus combination along with
the decreases in growth and colony formation suggest changes in TNBC cell line
survival, viability, and proliferation. In order to further understand how the treatment
combination has led to the observed effects we explored cell death mechanisms to
understand these decreases and synergy. Many cancer therapeutics decrease cancer
cell growth by initiating apoptosis or cell suicide when the genetic material becomes
damaged enough to trigger death. When apoptosis is initiated, pro-caspases are
cleaved to their activated state and start the cascade leading to cell death.
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Figure 9: Gefitinib and temsirolimus combination decreases TNBC cell growth
and colony formation.

A. Cell growth assays were done on BT20, MDA-MB-231, and MDA-MB-468 cells over
8 days in triplicate. Cells were treated every other day with 1 µM and counted on days
1,4, and 8 with a hemacytometer. ANOVAs were performed on GraphPad Prism
software with a significant decrease with the combination of gefitinib and temsirolimus
(GEF+TEM 1 µM) in all three cell lines. B. Colony formation assays were plated in a 6
well plate in triplicate. Treatments were done every other day at 1 µM for two weeks in
BT20 cells and 10 µM in MDA-MB-231 and MDA-MB-468. Cells were trypsinized,
replated at a low density, and allowed to grow for another week in normal growth media.
Colonies were counted on a Cell Counter. ANOVAs were done in GraphPad Prism
software and found a significant decrease in colony formation in the gefitinib and
temsirolimus (GEF+TEM) combination (blue bars). p*<0.05 **<0.01 ***0.001 ****0.0001
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Cleaved caspases are therefore a good marker for induction of apoptosis, along with
cleavage of another late stage apoptosis associated protein, PARP. We used
immunoblotting to look at three cleaved caspases 3, 7, and 9 and cleaved PARP as
indicators of apoptosis (Figure 11). There was no increase in apoptotic markers
observed in the MDA-MB-231 or MDA-MB-468 cells after 72 hour of treatment.
Treatment time courses from 0 to 72 hour were performed to ensure markers of
apoptosis were not missed in these studies.
mTOR is known to play a role in autophagy, another mechanism of cell death
(Laplante and Sabatini, 2009). mTOR controls autophagy in times of cell stress and can
initiate the recycling of cellular components when nutrients are scarce or in response to
certain chemotherapy drugs (Albert et al., 2010). A marker for autophagy is the
observance of increased compartments within the cell called autophagosomes that can
be observed under the microscope and the increased levels of converted LC3. After
treatment with the inhibitors, there appeared to be no increase in autophagosome
formation across the treatments (observed data not shown). Further immunoblotting
shows no increase in LC3 conversion suggesting that autophagy plays a minimal role in
the observed synergy (Figure 11).
The data suggest only a decrease in cell growth and colony formation, not a
complete inhibition (Figure 9). The growth curves slow over time (8 day time point)
suggesting a potential role for a cytostatic effect of gefitinib and temsirolimus
combination. Cytostasis is the process by which cells are removed from the cell cycle
therefore they are unable to proliferate. Cellular markers of cytostasis include the
accumulation in p21 and p53, two proteins that, when increased, stop progression of the
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cell cycle. Interestingly, there was an increase in both proteins with the combination
treatment. p53 levels increase after 24 hours while p21 levels take 48 hours to increase,
as shown through immunoblotting (Figure 11). Our results are in agreement with other
studies that have found the combination of EGFR and mTOR inhibitors is cytostatic
(Boffa et al., 2004; La Monica et al., 2009).
5.3 Conclusions
The phospho-proteomic data suggest a role for the mTOR pathway in EGFR
inhibitor resistance in TNBC cell lines. The data also propose that TNBC cell lines are
resistant to single agent mTOR inhibition (Albert et al., 2010; Buck et al., 2006). Further,
MTT viability found that the combination of EGFR and mTOR inhibitors was synergistic
and significantly decreased cell growth and colony formation compared to single agent
treatment. The lack of activation of caspases and PARP cleavage suggests a minimal
role of apoptosis and a lack of LC3 conversion supports a minimal role for autophagy as
being a mechanism of the observed decrease in cell growth and colony formation.
However, the data suggest the cells are undergoing cytostasis and stalling their growth
instead of triggering cell death. Further, the addition of an mTOR inhibitor can sensitize
TNBC cell lines to EGFR inhibitor treatment and needs to be further explored in EGFR
overexpressing TNBC as a treatment option. As the effect appears to be cytostatic, the
addition of a cytostatic drug along with EGFR and mTOR inhibition also needs to be
explored as a treatment option. While these results confirm what others have seen with
the combination of an EGFR and mTOR inhibitor in cancer cell lines, the mechanism of
action is still unknown, which we wanted to further explore.
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Figure 10: Gefitinib and temsirolimus synergize in TNBC cells.
	
  

	
  

	
  
A. The GI50 curve for BT20 cells was plotted in the presence of gefitinib (GEF),
temsirolimus (TEM) or the combination (GEF+TEM). The combination treatment
decreases the GI50 for the three cell lines (blue lines compared to red or green).
Calculations done in CalcuSyn B. Isobolograms were made by plotting the GI50 of GEF
on the Y axis and TEM on the X axis. Points falling below the drawn line indicate a
synergistic effect of the drug combination at a constant ratio.
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Figure 11: Cell death and senescence in gefitinib and temsirolimus treated TNBC.

	
  	
  

After 72 hour 1 µM treatment of gefitinib (GEF) and/or temsirolimus (TEM) in MDA-MB231 and MDA-MB-468 cells, there is no increase in cleavage of common apoptosis
proteins including Caspases 3, 7, 9, and PARP. Autophagy associated protein LC3 also
has minimal fluctuation after 72 hours indicating apoptosis and autophagy do not play a
major role in the reduction of TNBC viability, cell growth, and colony formation.
Increased p21 and p53 are markers for cytostasis. MDA-MB-231 and MDA-MB-468
cells have increased p21 and p53 after 1 µM treatment with GEF+TEM after 24 and 48
hours.
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CHAPTER 6: Signaling in the presence of EGFR and mTOR inhibitors
6.1 Introduction
After observing the synergy and significant decrease in growth and colony
formation from the combination of gefitinib and temsirolimus, we sought to find the
protein(s) that are responsible for regulating the observed effects. The EGFR has many
sites that can be phosphorylated to induce growth signaling and stress response
pathways, and sites that, when phosphorylated induce receptor internalization. While
the TNBC cells are resistant to EGFR inhibitor treatment, they still respond to EGFR
inhibitors

through

receptor

dephosphorylation

but

not

at

all

sites.

This

dephosphorylation is a good indicator of drug potency and brings up the question of
signaling crosstalk within the cell since, even though the receptor itself no longer
contains the signaling phosphate, downstream effector proteins are still activated. While
a detailed analysis of the different phosphorylation sites on the EGFR and their
signaling output is beyond the scope of this work, an excellent review on the subject
was written by Jorissen et al., 2002. A diagram of EGFR sites and their signaling
effector molecules can be seen in Figure 3.
6.2 Results
6.2.1 EGFR remains phosphorylated in the presence of gefitinib and temsirolimus
Immunoblot analysis on BT20 cells showed that many of the common
phosphorylation sites on the EGFR are dephosphorylated when treated with gefitinib (1
µM [Figure 12]). While some sites are dephosphorylated, known downstream proteins
may still be activated by other mechanisms e.g., Y1068 and MAPK (Figure 12, row 6).
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Figure 12: EGFR phosphorylation sites after EGFR and mTOR inhibitor treatment.
	
  
	
  

	
  
Treatment with gefitinib is able to abrogate EGFR phosphorylation on many sites.
Resistance to gefitinib in BT20 cells has allowed for alternate activation of effector
proteins even when the phosphorylation site is inhibited (Row 6 Y1068 and MAPK).
Gefitinib is unable to dephosphorylate Y992 and there is subsequent activation of the
corresponding effector protein PKC (row 4). Cells were treated with 1 µM gefitinib
and/or temsirolimus for 24 hours, whole cell lysates were separated on a SDS-PAGE
gel.
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It is of note that total EGFR levels decrease when treated with GEF+TEM suggesting
the combination is able to stimulate internalization of the receptor, possibly in a manner
similar to EGFR antibodies. When an EGFR antibody (e.g., cetuximab, panitumumab)
binds the receptor, it triggers a conformational change, which often leads to receptor
internalization. This makes the action of the drug two fold, it inhibits the ability of the
receptor to phosphorylate downstream effector proteins, and it promotes internalization
leading to decreased EGFR levels on the cell membrane able to bind growth factor
signals.
6.2.2 Activation of MAPK signaling pathways in the presence of temsirolimus and
gefitinib
We further performed immunoblot analysis on BT20, MDA-MB-231, and MDAMB-468 cell lines to determine if classical proteins involved in EGFR and mTOR
signaling were affected by dual inhibition of EGFR and mTOR (Figure 13). Specifically,
phosphorylation of MAPK, p38MAPK, and AKT along with total protein controls were
blotted for after 24 hour treatment with gefitinib and/or temsirolimus. EGFR classical
pathway activation is through the Ras-Raf-MEK-MAPK cascade or stress signaling
through p38MAPK. mTOR is part of the AKT/PI3K pathway. Unexpectedly, MAPK and
p38MAPK phosphorylation was not changed with the single or combination treatments
(Figure 13, rows 1 and 3). In contrast, p-AKT increased with temsirolimus treatment in
BT20 cells while remaining fairly constant in MDA-MB-231 and MDA-MB-468 while
gefitinib had no effect compared to untreated (Figure 13, row 5). mTOR inhibitors are
known to be ineffective as single agents as AKT has an activating feedback loop when
mTOR is inhibited as seen in BT20s (Hennessy et al., 2005; Wang et al., 2008). Our
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results show that, taken together, the classical pathways involved in EGFR and mTOR
signaling remain activated with gefitinib and temsirolimus treatment and are likely not
involved in the synergy we observe with the combination in TNBC cell lines.
6.3 Conclusions
Both the EGFR and mTOR pathways are linked with signaling cascades that can
lead to tumorigenesis. Our results indicate that the most commonly associated
pathways linked with EGFR and mTOR remain activated with gefitinib and temsirolimus
combination treatment suggesting they are not responsible for the observed synergy.
Our data indicate that MAPK, p38, and AKT are not the major players that are inhibited
with treatment leading to the decrease in growth and colony formation and further
experiments need to be done to elucidate the proteins responsible for the observed
synergy.
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Figure 13: MAPK and AKT signaling remain activated in the presence of EGFR
and mTOR inhibitors.	
  
	
  
	
  

	
  
Immunoblot analysis of TNBC cell lines. Cells were treated with 1 µM GEF and/or
TEM for 24 hours. Lysates were electrophoresed on a SDS-PAGE gel and
transferred to a PDVF membrane. There is minimal change in phosphorylation
across all treatments in TNBC cell lines with the main signaling proteins associated
with EGFR and mTOR signaling, MAPK, p38, and AKT, respectively. No decrease in
phosphorylation with the combination of GEF+TEM suggests a minimal role for
these proteins in regulating the observed synergy.
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CHAPTER 7: Role of eIF4B
7.1 Introduction
The common signaling proteins involved in EGFR and mTOR signaling did not
offer an explanation for the synergy we observe with gefitinib and temsirolimus dual
treatment. Upon returning to the phospho-proteomic data, it was seen that many of the
proteins that remained activated are involved in translation. mTOR controls translation
initiation through downstream effector proteins P70S6K and 4E-BP1. Translation is
often overactive in cancer and while it is usually a highly controlled process, when
mTOR is misregulated as often happens in cancer, oncogenic proteins are translated at
a greater rate leading to increased carcinogenesis (Loreni et al., 2013; Silvera et al.,
2010).
Upon activation, mTOR phosphorylates two effector proteins involved in
translation, P70S6K and 4E-BP1 (Raught et al., 2004; van Gorp et al., 2009). P70S6K
as described above, controls the phosphorylation of initiation factor eIF4B and 4E-BP1.
The latter sequesters eIF4E rendering it inactive. eIF4B facilitates eIF4A helicase
activity while eIF4E is the rate limiting factor in formation of the cap-binding complex,
eIF4F (Raught et al., 2004; Roux et al., 2007; Silvera et al., 2010). Translation begins
when the 40S ribosome binds the newly formed eIF4F complex containing eIF4E,
eIF4G, and eIF4A (Gingras et al., 1999; Merrick, 2004). When eIF4B is phosphorylated
it makes the helicase activity of eIF4A more efficient (Gingras et al., 1999; Shahbazian
et al., 2010a).
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7.2 Results
7.2.1 eIF4B phosphorylation is lost with the combination of temsirolimus and
gefitinib in TNBC
We analyzed the expression and phosphorylation of a number of translation
initiation proteins (Figure 14). Immunoblotting of the eIF4 family showed no change in
protein expression across the treatments.

However, eIF4B phosphorylation was

completely abrogated with the combination gefitinib and temsirolimus while remaining
unchanged with single agent treatment consistently in each of the three cell lines
(Figure 14, row 1). These data suggest that inhibition of both EGFR and mTOR
signaling is required to abrogate eIF4B phosphorylation in the TNBC cell lines we
tested.
7.2.2 Decrease in eIF4B expression decreases cell viability in TNBC
We further measured cell viability when eIF4B is knocked down through siRNA
constructs. As there currently is no available eIF4B specific inhibitor, using siRNA
allowed us to directly target the translation initiation factor and compare knockdown to
EGFR and mTOR inhibitor treatment. Cell viability as measured through MTT showed a
similar drop in viability with GEF+TEM treatment compared to eIF4B knockdown in
MDA-MB-231 cells (Figure 15). There is a significant decrease between the #8 eIF4B
knockdown construct and NT, and #8 and a nonsilencing control. It is important to note
that #8 provided a more consistent and strong knockdown compared to #7. Our data
suggest that the EGFR and mTOR pathways converge on eIF4B and when both
pathways are inhibited, eIF4B is also inhibited, stalling translation initiation and
regulating the observed synergy.
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Figure 14: eIF4B phosphorylation is a fragile point in EGFR and mTOR signaling.	
  	
  
	
  
	
  
	
  

	
  
Immunoblot analysis of TNBC cells after treatment with 1 µM gefitinib (GEF) and/or
temsirolimus (TEM) for 24 hours. Lysates were collected and blotted for eIF4 family
member expression and phosphorylation after electrophoresis on a SDS-PAGE gel.
eIF4B phosphorylation is completely abrogated with the combination treatment and only
changes minimally when treated with single agent GEF or TEM in all three cell lines.
Other family members remain phosphorylated across the treatments.
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Taken together our data suggest that the regulation of translation initiation may be a
critical component of EGFR and mTOR inhibitor synergy in TNBC.
7.2.3 P70S6K and P90RSK are responsible for phosphorylating eIF4B
downstream of EGFR and mTOR signaling
Our data suggest that eIF4B is a point of convergence between the EGFR and
mTOR pathways. P90RSK and P70S6K are two kinases that phosphorylate eIF4B on
Ser422 (Shahbazian et al., 2006). P90RSK is a downstream effector of EGFR through
Ras-MAPK activation and P70S6K is downstream of PI3K/mTOR activation (Raught et
al., 2004). Through P90RSK activation, eIF4B is phosphorylated after growth factor
signaling from EGFR and a complex signaling network (Yarden and Sliwkowski, 2001).
To determine if P90RSK and P70S6K are involved in the activation of eIF4B
downstream of EGFR and mTOR in TNBC, we treated the cell lines with gefitinib and/or
temsirolimus then measured phosphorylation of P90RSK and P70S6K as surrogates for
activation of each protein through immunoblotting. We found that p-P90RSK (S380)
was inhibited with the combination of gefitinib and temsirolimus while remaining
activated with single agent treatment with gefitinib and temsirolimus (Figure 16).
Additionally, P70S6K phosphorylation is abrogated through mTOR inhibition and
immunoblotting showed inhibition with single agent treatment of temsirolimus and the
combination (Figure 16). Taken together, our results suggest both P90RSK and
P70S6K are kinases in the EGFR and mTOR pathways that may be responsible for
signaling to translation machinery through eIF4B in TNBC.
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Figure 15: eIF4B knockdown has a similar effect on cell viability as gefitinib and
mTOR combination.

	
  
When eIF4B is knocked down through siRNA (#7, 8) there is a significant decrease in
cell viability similar to that of the combination treatment of GEF+TEM (1 µM) in MDAMB-231 cells. Viability was determined through MTT assay after 72 hour drug treatment
and knock down. Immunoblotting of a concurrent 6-well plate shows #7 and #8
successfully knocked down eIF4B while the nonsilencing (non-silen) control had no
effect on protein levels.
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Figure 16: P70S6K and P90RSK are responsible for phosphorylating eIF4B
downstream of mTOR and EGFR signaling.

TNBC cells were treated with 1 µM gefitinib (GEF), 1 µM temsirolimus (TEM) or the
combination. Lysates were collected and immunoblotted with the indicated antibodies.
p-P90RSK is decreased with the combination while remaining active with single agent
treatment. p-P70S6K is inhibited through temsirolimus treatment alone and is a known
downstream target of mTOR inhibition. Both kinases are responsible for
phosphorylating eIF4B and provide a link between EGFR and mTOR signaling which
must be inhibited to get the observed synergy in BT20, MDA-MB-231, and MDA-MB468 cell lines. P90RSK is activated through EGFR signaling and P70S6K through
mTOR.
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7.2.4 P90RSK and P70S6K inhibition display similar characteristics to EGFR and
mTOR synergy
P90RSK and P70S6K are kinases that directly phosphorylate eIF4B (Shahbazian
et al., 2006). Our data suggest that when treated with temsirolimus, P70S6K was
dephosphorylated but only the combination of GEF+TEM was able to inhibit
phosphorylation

of

P90RSK.

To

more

specifically

test

the

effect

of

the

dephosphorylation of P70S6K and P90RSK on eIF4B we used two selective inhibitors
of P90RSK and P70S6K, BI-D1870 and AT7867, respectively (Table 9). As seen with
GEF+TEM combination treatment, when BI-D1870 and AT7867 (BI+AT) were combined
in all experimental cell lines, the combination was synergistic (Table 9). Figure 17
further shows a decrease in p-eIF4B only when treated with BI+AT. We tested the
growth effects of BI-D1870 and AT7867 on the TNBC cell lines over an 8 day period as
described previously. We saw a significant decrease in cell growth with single agent
treatment (BI orange and AT green line) but the combination of BI+AT (grey line)
decreased growth to the greatest extent (Figure 18). Together, our data demonstrate
that dual inhibition of P90RSK and P70S6K displays a similar phenotype as the EGFR
and mTOR inhibitor combination, further implicating P90RSK and P70S6K in the
pathway conferring synergy in TNBC cell lines.
7.2.5 Inhibiting EGFR and mTOR blocks cap-dependent translation
Eukaryotic cells use two types of translation, cap-dependent, and capindependent also known as internal ribosome entry site (IRES) translation (Merrick,
2004). Most proteins (95-97%) are translated through the cap-dependent machinery
and therefore utilize the eIF proteins to mediate translation, but cap-independent
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translation is possible for transcripts that have a special mRNA sequence that can bind
the ribosome without the cap (Merrick, 2004; van Gorp et al., 2009; Wendel et al.,
2004). We utilized a dual luciferase assay, which is able to measure both capdependent and cap-independent translation simultaneously after treatment with gefitinib
and temsirolimus. This allowed us to look at the effects of gefitinib and temsirolimus on
eIF4B activity through a measurement of its role in translation. Using the reporter
plasmid (11510:pFR_HCV_xb) we can measure the expression of firefly luciferase as
regulated by cap-dependent translation and the expression of renilla luciferase
regulated by cap-independent translation (Petersen et al., 2006). The two types of
translation were measured using a dual injector plate reader (Figure 19). Data are
presented as normalized cap-dependent/ cap-independent translation. There was a
significant decrease (p<0.05) in cap-dependent translation after combination treatment
of gefitinib and temsirolimus that was not observed with single agent treatment while
cap-independent translation remained unchanged by the drug treatments. Our results
suggest the combination treatment only decreases cap-dependent translation most
likely through the modulation of eIF4B. Treatment has a negligible effect on capindependent translation, which does not require eIF4B.
7.3 Conclusions
Direct inhibition of P90RSK and P70S6K further implicates eIF4B as an important
regulatory point downstream of EGFR and mTOR pathways and upon which they
converge to regulate translational control. Since the vast majority of proteins translated
within the cell are through a cap-dependent mechanism and therefore require eIF4B, a
potential mechanism of action for gefitinib and temsirolimus synergy is through inhibiting
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the translation of many proteins in TNBC cell lines (Merrick, 2004). The importance of
translation in cancer is beginning to gain notoriety in the field and our data provide
further evidence suggesting translational control can play a major role in regulating drug
efficacy. EGFR and mTOR are two well-studied signaling proteins and much is known
about their pathways. However, our data suggest an important crosstalk between the
two signaling cascades that converge on eIF4B to regulate translational control and this
process may be exploited in drug development for TNBC. 	
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Table 9: GI50 values and synergy of BI-D1870 and AT7867.
	
  
BI-D1870
(RSK inhib)

AT7867
(S6K inhib)

BI+AT

CI value

BT20

7.41 µM

5.93 µM

2.73 µM

0.66

MDA-MB-231

9.57 µM

25.5 µM

3.24 µM

0.32

MDA-MB-468

5.79 µM

8.58 µM

3.54 µM

0.29

The GI50 values for the P90RSK inhibitor BI-D1870 and the P70S6K inhibitor AT7867
are presented. The CI values were also calculated using CalcuSyn software and the
combination was found to be synergistic in all three TNBC cell lines. BT20 CI<0.66,
MDA-MB-231 CI<0.32, MDA-MB-468 CI<0.29.
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Figure 17: BI-D1870 and AT7867 deceases p-eIF4B.

	
  
	
  
	
  
Combination treatment with BI-D1870 and AT7867 decreases p-eIF4B. Single agent
inhibition of p-P90RSK and p-P70S6K had minimal effects at decreasing the respective
kinases but when combined abrogate signaling.
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Figure 18: Growth assays with BI-D1870 and AT7867.

	
  
	
  
	
  
Cell growth assays were done on MDA-MB-468 cells over 8 days in triplicate. Cells
were treated every other day with 10 µM BI-1870 (BI) and/ or AT7867 (AT) and counted
on days 1, 4, and 8 with a hemacytometer. ANOVAs were performed on GraphPad
Prism software with a significant decrease with the combination of BI and AT compared
to NT and single treatment p*<0.05. There was also a significant decrease between NT
and AT in all cell lines and also in between NT and BI in BT20 and MDA-MB-231
p*<0.05.
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Figure 19: Inhibiting EGFR and mTOR signaling blocks cap-dependent
translation.

	
  

	
  	
  

The plasmid 11510:pFR_HCV_xb was transfected into HEK293T cells to measure capdependent translation through firefly luciferase and cap-independent translation through
renilla luciferase. Luciferase was measured using a dual-luciferase reporter assay
system from whole cell lysates. Values within each experiment were normalized to 1.0
as NT (no treatment). Relative light units from the firefly luciferase was plotted over
relative light units from the renilla luciferase. Each experiment was performed in
triplicate at least two times. There is a significant decrease (p<0.05) in translation with
GEF+TEM (blue bar) treatment. Treatments were for 24 hours at 1 µM. The decrease in
cap-dependent translation is further evidence implicating eIF4B dephosphorylation
through EGFR and mTOR inhibition is important in translation regulation. eIF4B
provides a point of convergence for the EGFR and mTOR pathways and their role in
regulating translation initiation.
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CHAPTER 8: STAT3 signaling in EGFR and mTOR synergy in TNBC
8.1 Introduction
STATs are known to play a role in many types of cancer including lung, breast,
and prostate (Quesnelle et al., 2007). These transcription factors can be activated by
cell surfaces receptors such as EGFR, and by mediary proteins including JAK and
mTOR before they translocate to the nucleus and control the transcription of certain
genes (Buettner et al., 2002). STAT3 is a known oncogene that has been studied in a
variety of cancers including lung, gastric, and breast (Table 5). The association of
STAT3 with EGFR and mTOR has been previously explored in gastric cancer and was
found to be a negative prognostic marker (Inokuchi M

et al., 2011). Elevated

expression of all three proteins within the gastric tumor correlated with a higher grade
and stage. Important to this work, STAT3 can be phosphorylated on two sites by EGFR
(Y705) and mTOR (S727) respectively. Both sites must be phosphorylated for full and
robust activation of STAT3. Signaling input from both the membrane bound EGFR and
cytoplasmic mTOR protein enable STAT3 to be controlled by many signals leading to
the transcription of genes often associated with a proliferative and tumorigenic
phenotype.
8.2 Results
8.2.1 STAT3 phosphorylation is lost in response to gefitinib and temsirolimus
Early studies found STAT3 as a potential target of EGFR/mTOR dual inhibition.
Specifically, we found a decrease in phosphorylation of STAT3 in all three TNBC cell
lines tested when treated with GEF+TEM while single agent treatment had no effect
(Figure 20). The phosphorylation of both Y705 and S727 was only decreased with the
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combination treatment. The continued phosphorylation of the individual sites with single
agent treatment further demonstrates TNBC cell line drug resistance to temsirolimus
and gefitinib as the EGFR is still able to signal to Y705 and mTOR to S727,
respectively. Only the combination causes a decrease in p-STAT3. These data suggest
that, similar to the phosphorylation of eIF4B, STAT3 may be a mediator of gefitinib and
temsirolimus synergy in TNBC.
8.2.2 A STAT3 inhibitor decreases cell viability and abrogates EGFR and mTOR
fragile point signaling
We sought to further investigate the role of p-STAT3 in conferring the synergy we
observe with EGFR and mTOR inhibitors. To determine if an inhibitor of STAT3 mimics
gefitinib and temsirolimus dual treatment, we utilized the STAT3 inhibitor (STATTIC).
STATTIC is a small molecule inhibitor that inhibits the dimerization domain of STAT3
and its phosphorylation at Y705 abrogating the transcription factor’s ability to signal. As
seen in Figure 21, STATTIC inhibits STAT3 phosphorylation to a greater extent than the
decrease seen in GEF+TEM as expected since it is a direct inhibitor. We then used
STATTIC treated cells and measured phosphorylation of other proteins in our predicted
EGFR and mTOR synergy pathway. A constitutively active Stat3c plasmid (described
below) was also used to overexpress active STAT3 and measure the effect on
phosphorylation of the proteins. We observed that STAT3 overexpression increased the
phosphorylation. Our data propose that STATTIC is able to abrogate p-P70S6K, pP90RSK, and p-eIF4B while Stat3c increases phosphorylation in p-P90RSK and peIF4B (Figure 21). The data suggest that STAT3 may also have a role in regulating
eIF4B and P90RSK and, when STAT3 is dephosphorylated, eIF4B and P90RSK are
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inactivated. While these results are preliminary and much more work would need to be
done to validate the role of STAT3 as an upstream signal or transcriptional regulator of
P90RSK and P70S6K, our data give exciting evidence for a more intricate crosstalk
mechanism within the cell.
8.2.3 Constitutively active STAT3 blocks gefitinib and temsirolimus synergy in
TNBC
Our results suggest STAT3 may play a role in regulating EGFR and mTOR
inhibitor synergy in TNBC cell lines. To further study the importance of STAT3 we
utilized a constitutively active STAT3 plasmid (Stat3c) transfected into TNBC cells and
then treated with gefitinib and temsirolimus to assess synergy. If STAT3 plays a vital
role in regulating EGFR and mTOR inhibitor synergy through its decreased
phosphorylation, a constitutively active STAT3 would negate the synergy. Gefitinib and
temsirolimus would be unable to modulate STAT3 activity and turn off the downstream
signaling pathways. Therefore, we performed MTT viability assays to determine if the
GEF+TEM combination had the same synergistic effect when STAT3 remained
phosphorylated through transfection of Stat3c.
Transfection efficiency as observed through the GFP tag on Stat3c is only about
30% in MDA-MB-231 and MDA-MB-468 cells and lower in BT20 (Figure 22 white cells
in Stat3c row compared to cells in Brightfield row, estimated transfection efficiency
based on visualized GFP positive cells). Immunoblotting for p-STAT3 performed
alongside the MTT viability study, shows after 72 hours, there is a marked increase in pSTAT3 (Y705) suggesting that the cells transfected with Stat3c do contain higher levels
of constitutively active STAT3. To determine if gefitinib and temsirolimus treatment
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Figure 20: Gefitinib and temsirolimus combination decreases p-STAT3.
	
  
	
  

	
  
TNBC cells were treated with 1 µM gefitinib (GEF), 1 µM temsirolimus (TEM) or the
combination. Lysates were collected and immunoblotted with the indicated antibodies.
p-STAT3 (Y705) and (S727) are decreased with the combination while remaining active
with single agent treatment. Both sites must be phosphorylated for full activation of
STAT3.
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Figure 21: STAT3 inhibition through STATTIC decreases EGFR and mTOR
regulated proteins.
	
  

	
  
	
  
STAT3 inhibition through STATTIC treatment decreases EGFR and mTOR related
proteins including p-eIF4B, p-P90RSK and p-P70S6K in a similar manner to EGFR and
mTOR dual inhibition through GEF+TEM. Stat3c transfected cells have increased
phosphorylation of proteins.
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Figure 22: Constitutively active STAT3 by Stat3c plasmid negates gefitinib and
temsirolimus synergy in TNBC cell lines.

	
  
Stat3c constitutively active plasmid was transfected into TNBC cells over 72 hours.
Immunoblotting was done to measure protein phosphorylation while fluorescent images
were also taken measuring transfection efficiency through the GFP tag on Stat3c. MDAMB-231 and MDA-MB-468 cells had the best transfection as measured though GFP and
immunoblotting. MTT cell viability assays were also done to determine gefitinib and
temsirolimus combination effect on the cells lines with Stat3c. CI values were calculated
using CalcuSyn software and the CI>1.0. BT20 CI<2.23, MDA-MB-231<1.07, MDA-MB468 <1.48. GFP positive green cells were changed to grey scale for better visualization
when printed to appear white on a black background instead of green.
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remained synergistic in cells transfected with Stat3c, synergy studies were performed
as described above in section 3.4 Using CalcuSyn to calculate the CI values in the
presence of Stat3c, we found that all three cell lines no longer exhibited synergy in
response to gefitinib and temsirolimus (CI=2.23 for BT20, CI=1.07 for MDA-MB-231,
and CI=1.48 for MDA-MB-468). These results support a role for STAT3 in regulating the
synergy observed when TNBC cells are treated with EGFR and mTOR inhibitors.
8.2.4 EGFR and mTOR inhibitors block STAT3 DNA binding
After STAT3 is phosphorylated it can homo- or heterodimerize, then translocate
to the nucleus to bind STAT3 DNA-binding elements and control gene expression
(Furqan et al., 2013). We have previously shown that GEF+TEM combination is able to
decrease STAT3 phosphorylation on both Y705 and S727 (Figure 20). In order to
measure STAT3 activity we utilized an ELISA (Figure 23). The ELISA is able to
qualitatively measure sample binding to a STAT3 response element oligo allowing us to
determine the effect of drug treatment on STAT3 activity. We found that MDA-MB-231
cells when treated with single agent gefitinib and temsirolimus (red and green bars) had
minimal effect on DNA binding ability. However, the combination (GEF+TEM, blue bar)
showed a significant decrease in STAT3 activity (p*<0.05). STATTIC treatment also had
a significant decrease in DNA binding. Taken together, our results suggest that EGFR
and mTOR dual inhibition decreases STAT3 phosphorylation on both Y705 and S727 to
modulate DNA binding. This decrease in STAT3 DNA binding is another mechanism of
action that may be responsible for the synergistic effects of gefitinib and temsirolimus in
TNBC cell lines.
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8.3 Conclusions
Immunoblot studies showed a decrease in STAT3 phosphorylation on both Y705
and S727 in response to GEF+TEM combination, while single agent treatment had no
effect on phosphorylation. Further studies demonstrated that inhibition of STAT3
through a small molecule inhibitor, STATTIC, decreased cell viability and also inhibited
the phosphorylation of interested proteins in the EGFR/mTOR pathway that are
important in regulating synergy; P90RSK, P70S6K, and eIF4B. Through constitutive
activation of STAT3 via plasmid transfection, we were able to negate the previously
observed synergy of GEF+TEM in all three TNBC cell lines suggesting that the
decreased phosphorylation of STAT3 is an important mediator of the EGFR and mTOR
inhibitor synergy. DNA binding ability of STAT3 was also significantly decreased when
treated with the drug combination. Our results provide evidence that STAT3 is an
important mediator of EGFR/mTOR inhibitor synergy in TNBC.	
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Figure 23: Gefitinib and temsirolimus in combination significantly decrease
STAT3 DNA binding.

STAT3 DNA binding was measured through an ELISA. There is a significant decrease
in DNA binding when treated with the GEF+TEM combination and STATTIC that is
absent in single agent treatment. p*<0.05 **<0.01
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CHAPTER 9: Conclusions
While survival rates for breast cancer patients are rising, those with TNBC
continue to have no suitable and successful drug therapy other than standard cytotoxic
chemotherapy. These patients do not respond to common hormone and HER2 driven
therapies since they do not express the cellular targets. TNBC patients have limited
non-surgical treatment options. Adjuvant cytotoxic chemotherapy is often given but high
resistance rates are common (Chacon and Costanzo, 2010; Santana-Davila R, 2010).
Research has been done in TNBC to find an effective targeted therapy that improves
the response rates while avoiding resistance and treatment limiting side effects. This
work focused on the overexpression of EGFR as TNBC often expresses high levels of
the receptor. Inhibitors targeting the EGFR are approved for different types of cancers
and, therefore, the receptor has potential to be exploited as a target in TNBC (Hawk,
2010; Santana-Davila R, 2010). Our research found that the mTOR pathway remained
activated in EGFR inhibitor resistant TNBC cell lines. Further evidence suggests that
mTOR and EGFR inhibitor combination has a synergistic effect at decreasing TNBC cell
viability and significantly decreases growth and colony formation. Our data confirm the
findings of others studying colon, prostate, and breast cancers that suggest the use of
mTOR inhibitors in combination with EGFR inhibitors to be of potential benefit (Bianco
et al., 2008; Liu et al., 2011). Everolimus was shown to sensitize GEO colon, PC3
prostate, and MDA-MB-468 TNBC cells to gefitinib and cetuximab and decrease their
growth in a dose-dependent manner. Using mouse xenografts the study showed a
decrease in colon cancer tumor burden by 90% when the drugs were used in
combination (Bianco et al., 2008). While EGFR inhibitors as monotherapy have not
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been effective due to intrinsic resistance, our results and those of others suggest that
combinations of EGFR and mTOR inhibitors are synergistic and their combined
potential as a targeted therapy in TNBC needs to be further studied (Liu et al., 2011;
O'Regan and Hawk, 2011).
Similar to published studies, our work found that dual treatment with gefitinib and
temsirolimus had a synergistic effect on decreasing TNBC cell viability, growth, and
clonogenic survival. While the combination of EGFR and mTOR inhibitors has been
previously observed in TNBC, the mechanism of synergy is not understood. Our studies
found an EGFR and mTOR crosstalk involving eIF4B and STAT3 that provides
evidence for regulating the observed synergy.
Inhibiting both EGFR and mTOR signaling was required to abrogate eIF4B
phosphorylation and subsequent cap-dependent translation in TNBC cell lines. Cancer
cells have an increased metabolic and proliferative rate requiring a high demand for
available protein. Aberrant translation has been implemented in cancer progression for
a number of years as patients with ribosomal disorders have an increased cancer risk
(Loreni et al., 2013; Montanaro et al., 2012). eIF4E is often considered an oncogene as
it was shown to induce transformation in cells (Lazaris-Karatzas et al., 1990). eIF4E is a
member of initiation factors that have altered expression in different types of cancer
(Silvera et al., 2010). Current research has also explored the potential benefit of
targeting the eIF4F complex in BRAF inhibitor resistant melanoma, colon, and thyroid
cancer cell lines. The authors, published in the most current issue of Nature, reported
that patient tumors resistant to inhibitors had increased activation of eIF4F resulting in
higher cap-dependent translation (Boussemart et al., 2014). In the same issue, another
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group discovered the oncogene ability of eIF4A in T-ALL and an inhibitor of eIF4A was
able to decrease ALL cell growth (Wolfe et al., 2014). It was previously discovered that
the MAPK and mTOR/PI3K pathways converge on eIF4B but to our knowledge this is
the first evidence of EGFR and mTOR inhibitor synergy being regulated by eIF4B in
TNBC (Shahbazian et al., 2006). Taken together, these results have identified a new
fragile point, eIF4B phosphorylation, and cap-dependent translation as a mediator of
EGFR and mTOR crosstalk in TNBC.
Our results suggest that the common EGFR and mTOR signaling proteins,
MAPK and AKT, are not responsible for regulating the synergy. Inhibiting EGFR and
mTOR through gefitinib and temsirolimus had no effect on MAPK and AKT
phosphorylation. This result corresponds with other studies in colon and lung cancer
that found AKT and MAPK maintain activity after EGFR and mTOR inhibitor treatment
(Bianco et al., 2008; La Monica et al., 2009). While MAPK and AKT are often
considered the main signaling proteins for the EGFR and mTOR pathways,
respectively, our data suggest a more prominent role for P70S6K and P90RSK in TNBC
cell lines resistant to EGFR inhibitors. P90RSK is downstream of MAPK and known to
be up regulated in breast and prostate cancer. It can activate P70S6K through direct
phosphorylation or through mTOR activation (Clark et al., 2005; Hennessy et al., 2005;
Romeo and Roux, 2011). Both P90RSK and P70S6K are involved in protein translation
through their ability to directly phosphorylate eIF4B. P70S6K is also known to
phosphorylate another key translation factor, 4E-BP1. When 4E-BP1 is phosphorylated
it releases eIF4E, the rate-limiting step in translation initiation, allowing it to form the
eIF4F complex initiating translation. Our data suggest that P70S6K regulation through
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EGFR and mTOR inhibition acts independently of 4E-BP1 as immunoblotting indicates
no change in 4E-BP1 phosphorylation after treatment (data not shown). Instead the
gefitinib and temsirolimus combination inhibits eIF4B phosphorylation through P70S6K
and P90RSK inhibition and decreases cap-dependent translation leading to the synergy
we observe in TNBC cell lines.
STAT3 is a transcription factor that is implicated in the oncogenesis of many
types of cancer, including breast. It can be activated through a variety of signaling
proteins including EGFR and mTOR, which bind to individual phosphorylation sites
(Y705 and S727, respectively), both of which are required for full activation of STAT3.
Our data suggest STAT3 phosphorylation selectively decreases with GEF+TEM
combination while remaining unchanged with single agent treatment. Further evidence
using STATTIC, a STAT3 inhibitor, and Stat3c constitutively active plasmid found that
specific STAT3 activation is able to negate the synergistic effect we observe with
GEF+TEM as measured through cell viability MTT assays. Our data suggest that,
similar to eIF4B regulation, STAT3 is regulated downstream of EGFR and mTOR
signaling and may be responsible for regulating TNBC cell synergy.
Our studies identified EGFR and mTOR inhibitors as a potentially effective
treatment for TNBC and the drug combination needs to be further explored. In addition,
these studies suggest P90RSK and P70S6K must be abrogated to mediate the
synergistic effects of gefitinib and temsirolimus combination. The effect translation has
on cancer cells in regard to the mTOR and EGFR pathways is largely unexplored in
TNBC and further implicates eIF4B as a protein of interest in understanding the gefitinib

	
  

	
  

99	
  
	
  
and temsirolimus synergy. We further present evidence suggesting that STAT3 may
also play a role in regulating synergy through DNA binding control.
TNBC has limited therapeutic options and this project sought to find a drug
combination to circumvent EGFR resistance using a phospho-proteomic approach.
While EGFR and mTOR inhibitors are approved in the clinic for various types of cancer.
Confirming the results of others, we suggest a potential use for EGFR/ mTOR inhibitor
combination in TNBC that needs to be further explored. The mechanism of action for
their observed synergy was previously unknown but we suggest it is through
translational control by eIF4B, and transcriptional regulation by STAT3. TNBC is a
highly malignant disease and through the data presented in this dissertation, another
therapeutic option may become available for patients in the future.
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APPENDIX
Supplemental Figure 1: Proposed pathway diagram.

Proposed pathway involving EGFR and mTOR proteins that are involved in regulating
synergy to gefitinib and temsirolimus combination in TNBC cell lines. Only when used in
combination do the drugs inhibit eIF4B to reduce translation and STAT3 to control
transcription. Dashed lines between mTOR, P90RSK, and P70S6K indicate the ability of
these proteins to activate each other. Additionally, there may be an extra level of control
involving STAT3 regulation of eIF4B and P90RSK (dashed lines) that also contribute to
the observed synergy and decreases in growth and survival.
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Supplemental Table 1: Proteins identified by phospho-mass spectrometry as not
significantly changed after gefitinib treatment.
Gene description
182 kDa tankyrase-1-binding protein
3-hydroxyacyl-CoA dehydratase 3
3-phosphoinositide-dependent protein kinase 1
40S ribosomal protein S3 OS=Homo sapiens
60S acidic ribosomal protein P0
60S acidic ribosomal protein P1
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
2
Acetyl-coenzyme A synthetase, cytoplasmic
Adenylyl cyclase-associated protein 1
Alpha- and gamma-adaptin-binding protein p34
Alpha-taxilin OS=Homo sapiens
AMP deaminase 2 OS=Homo sapiens
Antigen KI-67 OS=Homo sapiens
AP2-associated protein kinase 1
AP-3 complex subunit delta-1
Arfaptin-1 OS=Homo sapiens
Astrocytic phosphoprotein PEA-15
Ataxin-2-like protein
ATP-binding cassette sub-family F member 1
AT-rich interactive domain-containing protein 1A
BAG family molecular chaperone regulator 3
Bcl-2-associated transcription factor 1
Beta-2-syntrophin
Bifunctional aminoacyl-tRNA synthetase
Brefeldin A-inhibited guanine nucleotide-exchange
protein 2
Bystin
CAD protein
Calnexin
cAMP-dependent protein kinase type I-alpha
regulatory subunit
cAMP-dependent protein kinase type II-alpha
regulatory subunit
Catenin alpha-1
Catenin delta-1
Cation-independent mannose-6-phosphate receptor

	
  

	
  

Accession Number
TB182_HUMAN
HACD3_HUMAN
PDPK1_HUMAN (+1)
RS3_HUMAN
RLA0_HUMAN (+1)
RLA1_HUMAN (+1)
F262_HUMAN
ACSA_HUMAN
CAP1_HUMAN
AAGAB_HUMAN
TXLNA_HUMAN
AMPD2_HUMAN
KI67_HUMAN
AAK1_HUMAN
AP3D1_HUMAN
ARFP1_HUMAN
PEA15_HUMAN
ATX2L_HUMAN
ABCF1_HUMAN
ARI1A_HUMAN
BAG3_HUMAN
BCLF1_HUMAN
SNTB2_HUMAN
SYEP_HUMAN
BIG2_HUMAN
BYST_HUMAN
PYR1_HUMAN
CALX_HUMAN
KAP0_HUMAN
KAP2_HUMAN
CTNA1_HUMAN
CTND1_HUMAN
MPRI_HUMAN
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CCAAT/enhancer-binding protein beta
Cleavage and polyadenylation specificity factor
subunit 2
Cleavage stimulation factor subunit 3
Coatomer subunit beta'
Cofilin-1
Coiled-coil domain-containing protein 6
Coiled-coil domain-containing protein 86
CTTNBP2 N-terminal-like protein
Cyclin-dependent kinase 1
Cyclin-dependent kinase 12
Death-associated protein 1
Death-inducer obliterator 1
Density-regulated protein
Destrin
DNA repair protein complementing XP-C cells
DNA repair protein XRCC1
DNA replication licensing factor MCM2
DNA topoisomerase 2-beta
DOCK3_HUMAN-R
Double-strand break repair protein MRE11A
Drebrin-like protein
Dual specificity testis-specific protein kinase 1
Dynein heavy chain 14, axonemal
E3 SUMO-protein ligase RanBP2
E3 ubiquitin-protein ligase BRE1A
E3 ubiquitin-protein ligase CHIP
E3 ubiquitin-protein ligase HUWE1
E3 ubiquitin-protein ligase TRIM33
E3 ubiquitin-protein ligase ZFP91
Echinoderm microtubule-associated protein-like 4
EFCB6_HUMAN-R
Elongation factor 1-beta
Elongation factor 1-delta
Enhancer of mRNA-decapping protein 4
Epidermal growth factor receptor kinase substrate 8like protein 2
Epidermal growth factor receptor
Epiplakin
Eukaryotic translation initiation factor 2A
Eukaryotic translation initiation factor 3 subunit B
Eukaryotic translation initiation factor 3 subunit C
	
  

	
  

CEBPB_HUMAN
CPSF2_HUMAN
CSTF3_HUMAN
COPB2_HUMAN
COF1_HUMAN
CCDC6_HUMAN
CCD86_HUMAN
CT2NL_HUMAN
CDK1_HUMAN
CDK12_HUMAN
DAP1_HUMAN
DIDO1_HUMAN
DENR_HUMAN
DEST_HUMAN
XPC_HUMAN
XRCC1_HUMAN
MCM2_HUMAN
TOP2B_HUMAN
DOCK3_HUMAN-R
MRE11_HUMAN
DBNL_HUMAN
TESK1_HUMAN
DYH14_HUMAN
RBP2_HUMAN
BRE1A_HUMAN
CHIP_HUMAN
HUWE1_HUMAN
TRI33_HUMAN
ZFP91_HUMAN
EMAL4_HUMAN
EFCB6_HUMAN-R
EF1B_HUMAN
EF1D_HUMAN
EDC4_HUMAN
ES8L2_HUMAN
EGFR_HUMAN
EPIPL_HUMAN
EIF2A_HUMAN
EIF3B_HUMAN
EIF3C_HUMAN

103	
  
	
  
Eukaryotic translation initiation factor 3 subunit D
Eukaryotic translation initiation factor 3 subunit G
Eukaryotic translation initiation factor 3 subunit J
Eukaryotic translation initiation factor 4 gamma 1
Eukaryotic translation initiation factor 4E-binding
protein 1
Eukaryotic translation initiation factor 5
Eukaryotic translation initiation factor 5B
FACT complex subunit SSRP1
Fatty acid synthase
Ferritin heavy chain
FH1/FH2 domain-containing protein 1
FIL1L_HUMAN-R
Filensin
FK506-binding protein 15
General transcription factor II-I
Glucocorticoid receptor DNA-binding factor 1
Glucosamine--fructose-6-phosphate aminotransferase
[isomerizing] 1
Glycogen [starch] synthase, muscle
Glycogen synthase kinase-3 alpha
Golgi reassembly-stacking protein 2
Golgi-specific brefeldin A-resistance guanine
nucleotide exchange factor 1
H/ACA ribonucleoprotein complex subunit 4
Heat shock protein beta-1
Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta
Hepatoma-derived growth factor
Heterogeneous nuclear ribonucleoprotein H
Heterogeneous nuclear ribonucleoprotein K
Heterogeneous nuclear ribonucleoprotein U
Heterogeneous nuclear ribonucleoprotein U-like
protein 1
Heterogeneous nuclear ribonucleoprotein U-like
protein 2
Heterogeneous nuclear ribonucleoproteins A2/B1
High mobility group protein HMG-I/HMG-Y
Histone deacetylase 2
Histone demethylase UTY
Histone H1.2
Histone H1.5

	
  

	
  

EIF3D_HUMAN
EIF3G_HUMAN
EIF3J_HUMAN
IF4G1_HUMAN
4EBP1_HUMAN
IF5_HUMAN
IF2P_HUMAN
SSRP1_HUMAN
FAS_HUMAN
FRIH_HUMAN
FHOD1_HUMAN
FIL1L_HUMAN-R
BFSP1_HUMAN
FKB15_HUMAN
GTF2I_HUMAN
GRLF1_HUMAN
GFPT1_HUMAN
GYS1_HUMAN
GSK3A_HUMAN (+1)
GORS2_HUMAN
GBF1_HUMAN
DKC1_HUMAN
HSPB1_HUMAN
HS90A_HUMAN
HS90B_HUMAN (+1)
HDGF_HUMAN
HNRH1_HUMAN (+1)
HNRPK_HUMAN
HNRPU_HUMAN
HNRL1_HUMAN
HNRL2_HUMAN
ROA2_HUMAN
HMGA1_HUMAN
HDAC2_HUMAN
UTY_HUMAN
H12_HUMAN
H15_HUMAN
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HIV Tat-specific factor 1
Hsc70-interacting protein
IFRD2_HUMAN-R
Interferon regulatory factor 2-binding protein 2
Interferon regulatory factor 2-binding protein-like
KDM6A_HUMAN-R
Kelch domain-containing protein 4
Keratin, type I cytoskeletal 18
Keratin, type I cytoskeletal 19
Keratin, type II cytoskeletal 5
Keratin, type II cytoskeletal 7
Keratin, type II cytoskeletal 8
Kinectin
Lamina-associated polypeptide 2, isoform alpha
La-related protein 1
La-related protein 4
Large proline-rich protein BAG6
LIM and SH3 domain protein 1
LIM domain and actin-binding protein 1
Lupus La protein
Lysine-specific histone demethylase 1A
Mediator of DNA damage checkpoint protein 1
Membrane-associated progesterone receptor
component 1
Membrane-associated progesterone receptor
component 2
Methylosome subunit pICln
Microcephalin
Microfibrillar-associated protein 1
Misshapen-like kinase 1
Mitochondrial import receptor subunit TOM22 homolog
Mitogen-activated protein kinase 1
Mitotic checkpoint protein BUB3
Monocarboxylate transporter 1
Myb-binding protein 1A
Myc box-dependent-interacting protein 1
Myelin expression factor 2
Myosin-9
Nardilysin
Negative elongation factor B
Neuroblast differentiation-associated protein AHNAK
Niban-like protein 1
	
  

	
  

HTSF1_HUMAN
F10A1_HUMAN
IFRD2_HUMAN-R
I2BP2_HUMAN
I2BPL_HUMAN
KDM6A_HUMAN-R
KLDC4_HUMAN
K1C18_HUMAN
K1C19_HUMAN
K2C5_HUMAN
K2C7_HUMAN
K2C8_HUMAN
KTN1_HUMAN
LAP2A_HUMAN (+1)
LARP1_HUMAN
LARP4_HUMAN
BAG6_HUMAN
LASP1_HUMAN
LIMA1_HUMAN
LA_HUMAN
KDM1A_HUMAN
MDC1_HUMAN
PGRC1_HUMAN
PGRC2_HUMAN
ICLN_HUMAN
MCPH1_HUMAN
MFAP1_HUMAN
MINK1_HUMAN
TOM22_HUMAN
MK01_HUMAN
BUB3_HUMAN
MOT1_HUMAN
MBB1A_HUMAN
BIN1_HUMAN
MYEF2_HUMAN
MYH9_HUMAN
NRDC_HUMAN
NELFB_HUMAN
AHNK_HUMAN
NIBL1_HUMAN
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Nuclear autoantigen Sp-100
Nuclear cap-binding protein subunit 1
Nuclear pore complex protein Nup98-Nup96
Nuclear ubiquitous casein and cyclin-dependent
kinases substrate
Nuclear-interacting partner of ALK
Nuclease-sensitive element-binding protein 1
Nucleolar and coiled-body phosphoprotein 1
Nucleolar complex protein 2 homolog
Nucleolar protein 58
Nucleolar RNA helicase 2
Nucleolin
Nucleophosmin
Nucleosome assembly protein 1-like 4
Osteoclast-stimulating factor 1
Oxysterol-binding protein 1
Oxysterol-binding protein-related protein 11
Paralemmin-3
Partitioning defective 3 homolog
Paxillin
Periodic tryptophan protein 1 homolog
PERQ amino acid-rich with GYF domain-containing
protein 2
PHD and RING finger domain-containing protein 1
Phosphatidylinositol 4-kinase type 2-alpha
Pinin
Plakophilin-3
Pleckstrin homology-like domain family B member 2
Plectin
Prelamin-A/C
Probable E3 ubiquitin-protein ligase TRIP12
Proline-, glutamic acid- and leucine-rich protein 1
Proline-rich AKT1 substrate 1
Proline-rich protein 15
Protein arginine N-methyltransferase 3
Protein capicua homolog
Protein FAM83H
Protein kinase C and casein kinase substrate in
neurons protein 2
Protein KRI1 homolog
Protein PRRC2B
Protein PRRC2C
	
  

	
  

SP100_HUMAN
NCBP1_HUMAN
NUP98_HUMAN
NUCKS_HUMAN
NIPA_HUMAN
YBOX1_HUMAN
NOLC1_HUMAN
NOC2L_HUMAN
NOP58_HUMAN
DDX21_HUMAN
NUCL_HUMAN
NPM_HUMAN
NP1L4_HUMAN
OSTF1_HUMAN
OSBP1_HUMAN
OSB11_HUMAN
PALM3_HUMAN
PARD3_HUMAN
PAXI_HUMAN
PWP1_HUMAN
PERQ2_HUMAN
PHRF1_HUMAN
P4K2A_HUMAN
PININ_HUMAN
PKP3_HUMAN
PHLB2_HUMAN
PLEC_HUMAN
LMNA_HUMAN
TRIPC_HUMAN
PELP1_HUMAN
AKTS1_HUMAN
PRR15_HUMAN
ANM3_HUMAN
CIC_HUMAN
FA83H_HUMAN
PACN2_HUMAN
KRI1_HUMAN
PRC2B_HUMAN
PRC2C_HUMAN
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Protein scribble homolog
Protein strawberry notch homolog 1
Protein transport protein Sec61 subunit beta
Putative pre-mRNA-splicing factor ATP-dependent
RNA helicase DHX16
Putative protein phosphatase inhibitor 2-like protein 1
Putative protein phosphatase inhibitor 2-like protein 3
Rab11 family-interacting protein 1
Ral GTPase-activating protein subunit alpha-1
Ras GTPase-activating protein-binding protein 1
Ras-related protein R-Ras2
Regulation of nuclear pre-mRNA domain-containing
protein 1B
Regulator of microtubule dynamics protein 3
Reticulon-3
Reticulon-4
Retinoic acid-induced protein 3
Rho GTPase-activating protein 10
Rho GTPase-activating protein 12
Rho GTPase-activating protein 17
Rho guanine nucleotide exchange factor 5
Ribosomal L1 domain-containing protein 1
RING finger protein 113A
RNA-binding protein 39
RNA-binding protein NOB1
RNA-binding protein Raly
rRNA/tRNA 2'-O-methyltransferase fibrillarin-like
protein 1
Septin-2
Septin-9
Serine/arginine repetitive matrix protein 1
Serine/arginine repetitive matrix protein 2
Serine/threonine-protein kinase B-raf
Serine/threonine-protein kinase PAK 4
Serine/threonine-protein kinase PRP4 homolog
Serine/threonine-protein kinase SRPK1
Serine/threonine-protein kinase TAO3
Signal recognition particle receptor subunit alpha
Sister chromatid cohesion protein PDS5 homolog B
Small acidic protein
Sodium/hydrogen exchanger 1
Spectrin beta chain, brain 1
	
  

	
  

SCRIB_HUMAN
SBNO1_HUMAN
SC61B_HUMAN
DHX16_HUMAN
IPP2L_HUMAN
IPP2M_HUMAN (+1)
RFIP1_HUMAN
RGPA1_HUMAN
G3BP1_HUMAN
RRAS2_HUMAN
RPR1B_HUMAN
RMD3_HUMAN
RTN3_HUMAN
RTN4_HUMAN
RAI3_HUMAN
RHG10_HUMAN
RHG12_HUMAN
RHG17_HUMAN
ARHG5_HUMAN
RL1D1_HUMAN
R113A_HUMAN
RBM39_HUMAN
NOB1_HUMAN
RALY_HUMAN
FBLL1_HUMAN
SEPT2_HUMAN
SEPT9_HUMAN
SRRM1_HUMAN
SRRM2_HUMAN
BRAF_HUMAN
PAK4_HUMAN
PRP4B_HUMAN
SRPK1_HUMAN
TAOK3_HUMAN
SRPR_HUMAN
PDS5B_HUMAN
SMAP_HUMAN
SL9A1_HUMAN
SPTB2_HUMAN
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Splicing factor 1
Splicing factor 3B subunit 2
Splicing factor, arginine/serine-rich 19
Src substrate cortactin
Stathmin
Striatin
Structural maintenance of chromosomes protein 4
Sulfotransferase family cytosolic 2B member 1
Supervillin
Survival motor neuron protein
SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily A member 5
Synapse-associated protein 1
Synembryn-A
Target of Myb protein 1
TBC1 domain family member 9B
Telomeric repeat-binding factor 2-interacting protein 1
Tensin-3
Thioredoxin-related transmembrane protein 1
Thyroid hormone receptor-associated protein 3
Tight junction protein ZO-1
Tight junction protein ZO-2
Tight junction protein ZO-3
Tight junction-associated protein 1
Torsin-1A-interacting protein 1
TRAF-type zinc finger domain-containing protein 1
Transcription intermediary factor 1-beta
Transcriptional activator protein Pur-beta
Transmembrane and coiled-coil domains protein 1
Transmembrane protein 40
Treacle protein
Triosephosphate isomerase
Tripartite motif-containing protein 16
tRNA (cytosine-5-)-methyltransferase NSUN2
Tumor protein D54
Tumor suppressor p53-binding protein 1
U3 small nucleolar RNA-associated protein 14
homolog A
U3 small nucleolar RNA-associated protein 18
homolog
Ubiquitin carboxyl-terminal hydrolase 10
Ubiquitin-associated protein 2-like
	
  

	
  

SF01_HUMAN
SF3B2_HUMAN
SFR19_HUMAN
SRC8_HUMAN
STMN1_HUMAN
STRN_HUMAN
SMC4_HUMAN
ST2B1_HUMAN
SVIL_HUMAN
SMN_HUMAN
SMCA5_HUMAN
SYAP1_HUMAN
RIC8A_HUMAN
TOM1_HUMAN
TBC9B_HUMAN
TE2IP_HUMAN
TENS3_HUMAN
TMX1_HUMAN
TR150_HUMAN
ZO1_HUMAN
ZO2_HUMAN
ZO3_HUMAN
TJAP1_HUMAN
TOIP1_HUMAN
TRAD1_HUMAN
TIF1B_HUMAN
PURB_HUMAN
TMCC1_HUMAN
TMM40_HUMAN
TCOF_HUMAN
TPIS_HUMAN
TRI16_HUMAN
NSUN2_HUMAN
TPD54_HUMAN
TP53B_HUMAN
UT14A_HUMAN
UTP18_HUMAN
UBP10_HUMAN
UBP2L_HUMAN
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Uncharacterized protein C19orf21
UPF0414 transmembrane protein C20orf30
UV excision repair protein RAD23 homolog B
Vinexin
WD repeat-containing protein 44
WW domain-containing adapter protein with coiled-coil
Yorkie homolog
Zinc finger and BTB domain-containing protein 7A
Zinc finger CCCH-type antiviral protein 1
Zinc finger FYVE domain-containing protein 19
Zinc finger protein 185
Zyxin

CS021_HUMAN
CT030_HUMAN
RD23B_HUMAN
VINEX_HUMAN
WDR44_HUMAN
WAC_HUMAN
YAP1_HUMAN
ZBT7A_HUMAN
ZCCHV_HUMAN
ZFY19_HUMAN
ZN185_HUMAN
ZYX_HUMAN

Proteins identified by phospho-proteomic analysis whose phosphorylation
levels do not significantly change after gefitinib treatment. Phosphopeptides
were matched to proteomic databases for protein identification using Scaffold
software. The amount of phosphorylation was compared between the DMSO
vehicle control and gefitinib treated cells.
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Supplemental Figure 2: 11510:pFR_HCV_xb Dual reporter luciferase plasmid map.
	
  

	
  

The dual-reporter luciferase plasmid selectively measures capdependent translation through Firefly luciferase and cap-independent
translation through Renilla luciferase.
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Supplemental Table 2: Mutational status of common genes.

p53
BRCA
PTEN
PIK3CA
Kras
Hras
Braf
p16
p14ARF
rb1
chek2
myc

BT20
mut
wt
wt
mut
wt
wt
wt
del
del
wt
wt
wt

MDA-MB-231
mut
wt
wt
wt
mut
wt
mut
del
del
wt
wt
wt

MDA-MB-468
mut
wt
loss
wt
wt
wt
wt
wt
wt
del
wt
wt

	
  
	
  
Common genetic mutations and losses are described in the table arranged by TNBC
cell type. mut indicates a mutation, del a deletion, and wt indicates the gene is wild type.
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Supplemental Methods:
Phospho- Proteomics Analysis
BT20 cells were washed with ice cold HANK’s solution then proteins precipitated
with 100% EtOH before cell proteins were scraped from plates and transferred to
microcentrifuge tubes. Proteins were solubilized in 0.2 ml of Tris, 10 mM pH=7.5, LiF, 1
mM, Na3VO4, 0.1 mM, EDTA (Ethylenediaminetetraacetic acid) 1 mM and LiDS (Lithium
Dodecyl Sulfate) 0.5%. Non-soluble material was removed by filtration through Spin
Columns (Pierce, Rockford, IL, USA) and protein content determined by BCA protein
assay.

Samples were reduced with 10 mM dithiothreitol, alkylated with 30 mM

iodoacetamide and 900 µg protein digested with 1:100 TPCK-treated trypsin (Sigma)
after dilution to reduce LiDS concentration to 0.1% and addition of 10% acetonitrile.
Samples were filtered through 0.45 µm 13 mm GHP filters (Pall, Port Washington, NY,
USA) then phosphopeptides selected by incubation with 6 mg/sample TiO2 beads (GL
Sciences, Torrance, CA, USA, 5 µm).
The selectivity of the 6 mg of 5 µM TiO2 procedure for phosphopeptides was
95%. Cell digests were incubated with TiO2 in 2% TFA (Trifluoroacetic acid) saturated
with glutamic acid in 60% acetonitrile. The beads were washed three times with 1%
TFA in 60% acetonitrile before eluting phosphopeptides with NH4OH in 50% acetonitrile.
TiO2 elutes were neutralized with formic acid, dried under vacuum and stored at -80°C
until analysis. Eluted peptides solubilized in 0.1% formic acid were then analyzed by
LC-MS/MS (Liquid chromatography–mass spectrometry) without further purification.
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Mass Spectrometry: All analyses were performed on a Thermo LTQ equipped with ETD
(electron-disassociation transfer) (ThermoFisher Scientific, Watham, MA, USA).
Samples were loaded on a peptide Captrap (Michrom, Auburn, CA, USA) trapping
column and peptide separations achieved using a linear gradient of 5% to 35%
acetonitrile to elute from a Majic 0.1 mm x 150 mm AQ C18 column (Michrom). LCMS/MS was run in a neutral loss mode so that high abundance precursor neutral losses
of 24.25, 32.66, or 49.00 m/z found in an MS2 spectrum were selected for MS3
analysis.
Database Searching:

Tandem mass spectra were extracted by Proteome

Discoverer (ThermoFisher Scientific) version 1.4.0.288.

Charge state deconvolution

and deisotoping were not performed. All MS/MS data were analyzed using Mascot
(Matrix Science, London, UK; version 2.4.0) and X! Tandem (The GPM, thegpm.org;
version CYCLONE (2010.12.01.1)). Mascot and X!Tandem were each set up to search
the uniprot_sprot_20110405 database (selected for Homo sapiens, 20305 entries)
assuming the digestion enzyme trypsin. Spectra were searched with a fragment ion
mass tolerance of 0.70 Da and a parent ion tolerance of 3.5 Da. The iodoacetamide
derivative of cysteine was specified as a fixed modification. Oxidation of methionine,
acetylation of the N-terminus and phosphorylation of serine, threonine and tyrosine
were specified as variable modifications.
Criteria for Protein Identification:

Scaffold (version 4.0.5, Proteome Software

Inc., Portland, OR, USA) was used to validate MS/MS based peptide and protein
identifications. Peptide identifications were accepted if they could be established at
greater than 95.0% probability by the Peptide Prophet algorithm.(Keller et al., 2002)

	
  

	
  

113	
  
	
  
Protein identifications were accepted if they contained at least one identified
phosphopeptide and had a Protein Prophet probability greater than 80%.(Nesvizhskii et
al., 2003) Proteins that contained similar peptides and could not be differentiated based
on MS/MS analysis alone were grouped to satisfy the principles of parsimony.

All

subsequent analysis of protein sets included all proteins or peptides that met the criteria
for identification without weighting for the level of confidence in the identification.
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Triple negative breast cancer (TNBC) patients suffer from a highly malignant and
aggressive cancer that lacks an effective targeted therapeutic. Although many TNBCs,
both in vitro and in vivo, have increased expression of epidermal growth factor receptor
(EGFR), EGFR targeted inhibitors, such as gefitinib (GEF), have yet to demonstrate
efficacy. Using mass spectrometry to identify pathways that remain activated in the
presence of GEF, we found that components of the mTOR signaling pathway remain
phosphorylated. While inhibiting mTOR with temsirolimus (TEM) decreased mTOR
signaling, EGFR signaling pathways remained activated and the TNBC cell lines
continued to proliferate. However, dual treatment with TEM and GEF synergistically
decreased cell viability in TNBC cells. Interestingly, abrogation of both EGFR and
mTOR signaling did not alter the phosphorylation of key growth signaling molecules
including MAPK and AKT. Instead, our data have identified the translational control
pathway, specifically, eIF4B as a potentially key regulatory point in EGFR and mTOR
inhibitor synergy. Further, we have also identified the transcription factor, STAT3 as
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another regulatory point in the EGFR and mTOR inhibitor synergy. Therefore, in this
study we hypothesized that mTOR inhibition can sensitize TNBC cells to EGFR TKIs
through the inhibition of eIF4B and STAT3 phosphorylation.
eIF4B enhances the helicase activity of eIF4A during translation initiation. As
expected, knockdown of eIF4B expression decreased cell viability comparable to the
decrease observed with the combination treatment. Importantly, we have identified
p70S6K and p90RSK as kinases directly responsible for eIF4B phosphorylation, such
that both molecules need to be inactivated in order for eIF4B phosphorylation to be
abrogated. This inactivation correlated with a loss of cell growth and viability and a
decrease in clonogenic cell survival, potentially through alterations in the cell cycle.
Furthermore, cap-dependent translation was inhibited to a greater extent in the
combination treatment than GEF or TEM alone. Taken together these data suggest that
EGFR and mTOR inhibitor combination abrogates cell growth, viability, and survival via
disruption of translational control mechanisms through eIF4B.
STAT3 is a widely considered oncogenic transcription factor that has been
implicated in a variety of cancer types. We found a decrease in phospho-STAT3 with
the GEF+TEM combination. Further DNA binding ELISAs found STAT3 activity was
also significantly decreased with the combination. Overexpression of a constitutively
active STAT3 plasmid found that STAT3 activation negates the GEF+TEM synergetic
effect on cell viability. Together, these studies suggest a role for STAT3 in EGFR and
mTOR inhibitor synergy.
Taken together these data suggest that in the presence of activated MAPK and
AKT, EGFR and mTOR inhibitors abrogate growth, viability, and survival via disruption
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of eIF4B and STAT3 phosphorylation leading to decreased translation and transcription
factor DNA binding, respectively, in TNBC cell lines. The effect translation has on
cancer cells in regard to the mTOR and EGFR pathways is largely unexplored in TNBC
and further implicates eIF4B as a protein of interest in understanding the gefitinib and
temsirolimus synergy. TNBC patients currently have limited treatment options and our
data suggest that including an mTOR inhibitor along with an EGFR inhibitor in TNBC
with increased EGFR expression should be further explored.
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